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Background: The Japanese Society for Dialysis Therapy (JSDT) has performed a nationwide renal data registry
since 1966. The data from the survey have been used for promoting dialysis facilities to improve dialysis
quality and developing JSDT guidelines. Here, we summarized the current status of chronic dialysis in Japan
as of 31 December 2014.
Methods: The annual survey was conducted targeting for 4367 dialysis facilities by electrically and partially
paper-based; among which, 4330 (99.2%) responded. The results shown in this report are all descriptive, and
no statistical analyses were conducted.
Results: The number of the incident dialysis patients was 38,327 and that of the prevalent dialysis patients
was 320,448 in 2014. The count of prevalent dialysis patients per million population was 2517. The count
of dialysis patients who died in 2014 was 30,707, and the crude mortality rate was 9.6%. The mean age of
incident dialysis patients was 69.04 years, and the mean age of the prevalent dialysis patients was 67.54 years.
The most common primary cause on the incident and prevalent dialysis patients was diabetic nephropathy.
The patient count on hemodiafiltration (HDF) at the end of 2014 was 43,283; in particular, the number of
online HDF patients increased more than 2.5 times over the last 3 years. The facility survey showed that
9255 patients were on peritoneal dialysis (PD) in 2014. Among them, 1913 patients were treated by the
combination of PD and hemodialysis (HD) or HDF. The number of patients treated by home HD at the end
of 2014 was 529, a continued increase from that at the end of 2013 as 461.
Conclusions: The chronic dialysis population in Japan has been still increasing and becoming older year by
year. The rapidly increasing number of online hemodiafiltration is an emerging trend but the penetration rate
of home therapies by peritoneal dialysis and home hemodialysis was still the lowest in the world.
Trial registration: UMIN000018641
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Introduction
The Japanese Society for Dialysis Therapy (JSDT) has
been annually surveyed the status of chronic dialysis
since 1968, and it was named the JSDT renal data regis-
try (JRDR). In the early surveys, only the counts of
patients and dialysis-beds in dialysis facilities were* Correspondence: imasakan.aipod@seieig.or.jp
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unless otherwise stated.recorded annually. Since 1983, clinical data of all dialysis
patients treated in the facilities that participated in the
surveys have been collected. The results from these sur-
veys were summarized as the annual renal data report
and also used for making JSDT guidelines and standards.
JRDR is respected worldwide as an unbiased complete
patient census.
Before 2014, the results from JRDR had been reported
in following three types of report. First, quick analyses of
the data obtained by April in the following year were re-
ported at the annual meeting of the JSDT held in June
and compiled in “The Atlas, Overview of RegularOpen Access This article is distributed under the terms of the Creative
e (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
, provided you give appropriate credit to the original author(s) and the source,
se, and indicate if changes were made. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of chronic dialysis therapy in 2014
Number of facilities 4330 facilities (increase of 62 facilities, 1.5% increase)
Equipment Number of bedside consoles 131,555 units (increase of 3405 units, 2.7% increase)
Capacity Capacity for simultaneous HD
treatments
129,860 treatments (increase of 3600 patients, 2.9% increase)
Maximum capacity 432,433 patients (increase of 10,272 patientns, 2.4% increase)
Prevalent dialysis patients Daytime 269,393 patients (84.1%)
Nighttime 41,271 patients (12.9%)
Home HD 529 patients (0.2%)
PD 9255 patients (2.9%)
Total prevalent dialysis patients 320,448 patients (100.0%) (increase of 6010
patients)
Adjusted prevalent patient count (pmp) 2517.3 patients (increase of 47.2
patients)
Number of PD + HD patientsa 1913 patients
Number of non-PD + catheter patientsb 278 patients
Number of PD dropout patientsc 193 patients
Incident dialysis patients 38,327 patients (increase of 232 patients, 0.6% increase)
Deceased patients in 2014 30,707 patients (increase of 44 patients, 0.1% decrease)
The above data were obtained from the facility survey.
Dialysis vintage (years) Male Female Unspecified Total (%)
0≦, <5 98,411 47,674 0 146,085 (47.1)
5≦, <10 49,893 27,969 0 77,862 (25.1)
10≦, <15 24,330 15,702 0 40,032 (12.9)
15≦, <20 12,178 9035 0 21,213 (6.8)
20≦, <25 6368 5434 0 11,802 (3.8)
25≦, <30 3450 3101 0 6551 (2.1)
30≦, <35 2091 1869 0 3960 (1.3)
35≦ 1359 1158 0 2517 (0.8)




Total 198,141 111,967 0 310,108
Longest dialysis vintage 46 years and
6 months
The above data were obtained from the patient survey.
aPD + HD patients: Patients treated by the combination of PD and HD, HDF, hemoadsorption, or hemofiltration (excluding those who underwent only
peritoneal lavage)
bNon-PD + catheter patients: Patients who did not undergo PD despite having a peritoneal catheter but underwent HD, HDF, hemoadsorption, or hemofiltration
(including those who underwent only peritoneal lavage)
cPD dropout patients: Incident PD patients who changed a dialysis modality during 2014
pmp per million population
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to the survey had been continuously collected until
September, and the obtained data were screened to
determine the definite survey results, which were
published in the “An Overview of Regular Dialysis
Treatment in Japan, the CD-ROM Report”. Third, the
tabulated results based on the definite values in theCD-ROM report were published as an annual dialysis
data report in the Journal of Japanese Society for Dia-
lysis Therapy. Therefore, the values in the atlas were
different from the definite values in the CD-ROM.
The quick estimations were prepared only for the
atlas in the annual meeting of JSDT. However, the
values in the atlas had been occasionally cited as if
Table 2 Prevalent, incident, and deceased dialysis patient counts and adjusted rate
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Prevalent dialysis patients 154,413 167,192 175,988 185,322 197,213 206,134 219,183 229,538 237,710 248,166
Incident dialysis patients 26,398 28,409 28,870 29,641 31,483 32,018 33,243 33,710 33,966 35,084
Deceased dialysis patients 14,406 15,174 16,102 16,687 18,524 18,938 19,850 20,614 21,672 22,715
Adjusted prevalent dialysis patients (pmp) 1229.7 1328.4 1394.9 1465.2 1556.7 1624.1 1721.9 1801.2 1862.7 1943.5
Recovery rate for facility survey (%) 99.8 99.8 99.7 99.7 99.7 99.9 99.0 99.6 99.1 98.7
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Prevalent dialysis patients 257,765 264,473 275,242 283,421 290,661 298,252 304,856 310,007 314,438 320,448
Incident dialysis patients 36,063 36,373 36,934 38,180 37,566 37,512 38,613 38,055 38,095 38,327
Deceased dialysis patients 23,983 24,034 25,253 27,266 27,646 28,882 30,743 30,710 30,751 30,707
Adjusted prevalent dialysis patients (pmp) 2017.6 2069.9 2154.2 2219.6 2279.5 2329.1 2385.4 2431.2 2470.1 2517.3
Recovery rate for facility survey (%) 98.9 98.4 98.9 99.0 98.5 98.6 99.0 99.0 98.7 99.2
The above counts were from the facility surveys
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expressed by attractive graphs. To avoid these mal-
citations, we decided to publish all the official reports
from the 2014 survey based on the definite database.
All the figures and tables included in the CD-ROM
report have been made available on the members-only
pages of the JSDT website since 2012 to widely pro-
vide the survey findings among JSDT members. These
pages contain all the findings from the first survey
conducted in 1968 to the latest survey. All figures
and tables in the website in JRDR have been updating
if any errors had been found so these updated data
should be used for any academic and social analyses.
On the other hand, the summaries of survey resultsFig. 1 Annual increasing rate of incident dialysis patientsin the illustrated report are available for the general
public on the JSDT website (http://www.jsdt.or.jp/
overview_confirm.html). A review report should be re-
ferred for the historical background of the annual survey
and the survey items in the previous surveys [1].
The current manuscript is the second publication of
An overview of regular dialysis treatment in Japan (as of
December 31, 2014) J Jpn Soc Dial Ther 49(7):1–34,
2016, written in Japanese.
Subjects and methods
Survey method
The JSDT survey is conducted annually by sending ques-
tionnaires to all dialysis facilities in Japan at the end ofFig. 2 Annual increasing rate of deceased dialysis patients
Table 3 Modalities in prevalent dialysis patients
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Facility surveya Prevalent dialysis patient 248,166 257,765 264,473 275,242 283,421 290,661 298,252 304,856 310,007 314,438 320,448
(%) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
Daytime dialysis patient 196,337 206,340 213,454 223,953 231,517 238,848 246,146 253,916 258,131 263,184 269,393
(%) (79.1) (80.0) (80.7) (81.4) (81.7) (82.2) (82.5) (83.3) (83.3) (83.7) (84.1)
Nighttime dialysis patient 42,600 41,871 41,641 41,742 42,405 41,719 42,052 40,971 41,969 41,401 41,271
(%) (17.2) (16.2) (15.7) (15.2) (15.0) (14.4) (14.1) (13.4) (13.5) (13.2) (12.9)
Home HD patient 114 127 147 187 193 236 277 327 393 461 529
(%) (0.0) (0.0) (0.1) (0.1) (0.1) (0.1) (0.1) (0.1) (0.1) (0.1) (0.2)
PD patientc 8774 9243 9003 9362 9300 9858 9773 9642 9514 9392 9255
(%) (3.5) (3.6) (3.4) (3.4) (3,3) (3.4) (3.3) (3.2) (3.1) (3.0) (2.9)
PD + HD patientd 1720 1983 1902 1932 1920 1913
non-PD + catheter patiente 437 406 369 347 292 278
Patient surveyb Prevalent dialysis patient 236,606 240,513 249,957 264,356 273,237 281,996 289,449 295,735 301,545 306,925 310,108
(%) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
HD 213,474 216,880 223,737 235,960 245,090 253,807 262,973 270,072 268,275 264,211 255,641
(%) (90.2) (90.2) (89.5) (89.3) (89.7) (90.0) (90.9) (91.3) (89.0) (86.1) (82.4)
HDF 14,183 14,083 16,163 17,759 17,380 16,853 14,867 14,115 21,725 31,371 43,283
(%) (6.0) (5.9) (6.5) (6.7) (6.4) (6.0) (5.1) (4.8) (7.2) (10.2) (14.0)
PDc 8004 8103 7971 8630 8636 9164 9298 9094 8996 9037 8941
(%) (3.4) (3.4) (3.2) (3.3) (3.2) (3.2) (3.2) (3.1) (3.0) (2.9) (2.9)
aData obtained from the facility survey
bData obtained from the patient survey
cThe figures mean “number of CAPD patients” from 2002 to 2008 (CAPD: continuous ambulatory peritoneal dialysis)
dPD + HD patients: patients treated by the combination of PD and HD or HDF
eNon-PD + catheter patients: HD or HDF patients with PD catheter
Masakane et al. Renal Replacement Therapy  (2017) 3:18 Page 4 of 43each year. A total of 4367 facilities surveyed were either
member facilities of JSDT, nonmember facilities offering
regular maintenance hemodialysis (HD), or nonmember
facilities offering peritoneal dialysis (PD) but not HD as
of 31 December 2014. The number of facilities partici-
pating in this survey increased by 42 (1.0%) from 2013
as 4325 facilities [2].
The questionnaires were mainly sent and collected by
postal mail; the rest of them were also faxed. Universal
serial bus (USB) memory devices with stored electronic
spreadsheets in Microsoft Excel format were also sent
with the printed questionnaires to the facilities. The fa-
cilities were requested to use these devices for the com-
pletion of the questionnaires as much as possible.
In this survey, two sets of questionnaires were used.
One was for the facility survey, which included ques-
tions about dialysis facilities, such as the number of
patients and the number of staff members. The other
was for the patient survey, which included items on
the epidemiological background, treatment conditions,
and the outcome of the treatment of individual dialy-
sis patients.The deadline for the acceptance of responses was the
end of January in 2015. The acceptance of responses
submitted after this deadline, including those of the add-
itional surveys, ended on 7 August 2015.
As previously addressed, we decided to publish the
annual report based on the definite database from
2014, so all values in this report are officially ap-
proved and the same as those in the CD-ROM. Based
on the defined database, the count of facilities that
responded to the facility survey was 4330 (99.2%),
and the count of facilities that responded to both the
facility and patient surveys was 4191 (96.0%). More-
over, the facilities that completed the questionnaires
using the electronic medium (3764 facilities, 86.9%)
further increased from the 2013 survey (3698 facil-
ities, 86.6%). This increase contributed to the accurate
and simplified analysis of survey data [3].
Survey items
The collected data in the 2014 survey were classified
to the following two categories as facility data and
patient data. The items in the previous surveys are
Table 4 Prevalent dialysis patient counts by modality and prefecture
Prefecture Daytime Nighttime Home HD PD Total
Outpatients Inpatients Outpatients Inpatients Outpatients Inpatients Outpatients Inpatients
Hokkaido 11,733 1793 1277 32 10 0 384 10 15,239
Aomori 2885 226 231 2 0 0 85 3 3432
Iwate 2390 219 332 3 0 0 95 5 3044
Miyagi 4030 346 813 36 0 0 86 6 5317
Akita 1597 258 134 0 2 0 54 5 2050
Yamagata 1953 252 310 0 10 0 66 4 2595
Fukushima 3852 368 400 1 1 0 169 12 4803
Ibaraki 6098 600 885 0 5 0 112 15 7715
Tochigi 4736 431 704 0 2 0 86 2 5961
Gunma 4200 563 906 17 7 0 95 2 5790
Saitama 13,574 1080 1837 31 80 0 266 6 16,874
Chiba 10,972 1105 1630 10 6 0 270 4 13,997
Tokyo 22,033 2484 4919 112 65 1 1017 20 30,651
Kanagawa 14,710 1524 3082 41 32 0 530 74 19,993
Niigata 3607 291 971 12 1 0 155 3 5040
Toyama 1794 342 270 1 2 0 97 4 2510
Ishikawa 2019 237 316 0 2 0 68 1 2643
Fukui 1325 153 212 7 3 0 82 4 1786
Yamanashi 1800 117 246 0 1 0 58 0 2222
Nagano 3823 354 732 2 4 0 127 5 5047
Gifu 3672 439 610 7 22 0 81 3 4834
Shizuoka 8119 831 1289 4 12 0 174 9 10,438
Aichi 12,379 1397 3027 41 48 0 672 17 17,581
Mie 3333 387 498 18 5 0 78 1 4320
Shiga 2147 299 439 4 31 0 135 7 3062
Kyoto 4534 510 913 100 11 0 202 4 6274
Osaka 17,336 2087 2696 76 36 0 523 20 22,774
Hyogo 10,353 1081 1601 22 55 0 232 32 13,376
Nara 2699 234 265 2 6 0 152 3 3361
Wakayama 2357 279 264 23 16 0 38 1 2978
Tottori 1147 111 138 0 0 0 57 10 1463
Shimane 1203 104 142 0 1 0 57 8 1515
Okayama 3511 547 555 24 1 4 179 18 4839
Hiroshima 5603 844 636 2 22 1 350 27 7485
Yamaguchi 2561 477 315 5 0 0 132 5 3495
Tokushima 2106 260 241 1 4 0 160 13 2785
Kagawa 1932 273 210 3 8 0 184 5 2615
Ehime 2809 471 379 6 0 0 140 3 3808
Kochi 1694 303 260 31 0 0 20 4 2312
Fukuoka 10,276 1222 2171 62 3 0 641 20 14,395
Saga 1763 260 295 9 1 0 14 2 2344
Nagasaki 2924 386 482 9 3 0 129 3 3936
Kumamoto 4667 640 900 3 1 0 149 2 6362
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Table 4 Prevalent dialysis patient counts by modality and prefecture (Continued)
Oita 2916 487 325 5 3 0 146 2 3884
Miyazaki 2954 292 506 12 0 0 53 2 3819
Kagoshima 3928 669 531 24 1 0 127 24 5304
Okinawa 3297 409 576 0 0 0 96 2 4380
Total 241,351 28,042 40,471 800 523 6 8823 432 320,448
All figures were from the facility survey. They do not necessarily meet the total number of patients counted in accordance with dialysis modality
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site (http://www.jsdt.or.jp/).Facility survey
The following are the items surveyed in the 2014 survey
and are the same as those in the 2013 survey [2].
 Name and contact numbers (TEL, FAX) of facility
 Year and month when the facility started providing
dialysis treatment
 Capacity for simultaneous hemodialysis treatments
 Maximum capacity for hemodialysis treatments
 Number of bedside consoles
 Number of workers involved in dialysis treatment
(e.g., doctors, nurses, clinical engineers, nutritionists,
case workers)
 Number of dialysis specialists
 Number of prevalent dialysis patients at the end of
2014 (daytime dialysis, nighttime dialysis, home HD,
PD)
 Number of HD/HDF patients with PD catheter
(non-PD + catheter patients)
 Number of patients treated by the combination of
PD and HD/HDF (PD + HD patients)
 Number of inpatients on dialysis at the end of 2014
 Number of incident dialysis patientsTable 5 Mean age of prevalent and incident dialysis patients
1993 1994 1995
Mean age of the prevalent dialysis patients 56.6 57.3 58.0
±S.D. 13.5 13.5 13.4
Mean age of the incident dialysis patients 59.8 60.4 61.0
±S.D. 14.4 14.3 14.2
2004 2005 2006
Mean age of the prevalent dialysis patients 63.3 63.9 64.4
±S.D. 12.9 12.8 12.8
Mean age of the incident dialysis patients 65.8 66.2 66.4
±S.D. 13.4 13.4 13.4 Number of the incident PD patients who changed a
dialysis modality during 2014 (PD dropout patients)
 Number of deceased patients during 2014
 Number of bedside consoles equipped with an
endotoxin retentive filter (ETRF)
 Use or nonuse of ETRFs for sampling dialysis fluid
 Sampling site of dialysis fluid
 Frequency for measuring endotoxin concentration in
dialysis fluid
 Endotoxin concentration in dialysis fluid
 Frequency for measuring total viable microbial
count (TVC) in dialysis fluid
 Sampling volume for TVC
 Cultivation medium for TVC
 TVC in dialysis fluid
 Patient survey
The following are the basic survey items that have
been annually surveyed since 1983.
 Anonymized name
 Gender
 Date of birth
 Year and month of start of dialysis
 Year and month of transfer from another hospital
 Primary disease
 Residence (prefecture)1996 1997 1998 1999 2000 2001 2002 2003
58.6 59.2 59.9 60.6 61.2 61.6 62.2 62.8
13.4 13.4 13.3 13.3 13.2 13.1 13.0 12.9
61.5 62.2 62.7 63.4 63.8 64.2 64.7 65.4
14.2 14.0 13.9 13.9 13.9 13.7 13.6 13.5
2007 2008 2009 2010 2011 2012 2013 2014
64.9 65.3 65.8 66.2 66.6 66.9 67.2 67.5
12.7 12.7 12.6 12.6 12.6 12.5 12.5 12.5
66.8 67.2 67.3 67.8 67.8 68.5 68.7 69.0
13.3 13.3 13.3 13.3 13.4 13.4 13.4 13.4
Table 6 Incident dialysis patient distribution by gender and age
Age at dialysis
initiation
Male Female Subtotal No information
available
Total
<5 2 8 10 10
(%) (0.0) (0.1) (0.0) (0.0)
5~9 2 2 4 4
(%) (0.0) (0.0) (0.0) (0.0)
10~14 6 5 11 11
(%) (0.0) (0.0) (0.0) (0.0)
15~19 23 13 36 36
(%) (0.1) (0.1) (0.1) (0.1)
20~24 39 27 66 66
(%) (0.2) (0.2) (0.2) (0.2)
25~29 77 43 120 120
(%) (0.3) (0.4) (0.3) (0.3)
30~34 175 86 261 261
(%) (0.7) (0.7) (0.7) (0.7)
35~39 383 144 527 527
(%) (1.6) (1.2) (1.4) (1.4)
40~44 764 260 1024 1024
(%) (3.1) (2.2) (2.8) (2.8)
45~49 1052 370 1422 1422
(%) (4.3) (3.1) (3.9) (3.9)
50~54 1330 492 1822 1822
(%) (5.4) (4.2) (5.0) (5.0)
55~59 1770 680 2450 2450
(%) (7.2) (5.8) (6.7) (6.7)
60~64 2753 1045 3798 3798
(%) (11.2) (8.8) (10.4) (10.4)
65~69 3598 1471 5069 5069
(%) (14.7) (12.5) (13.9) (13.9)
70~74 3691 1687 5378 5378
(%) (15.0) (14.3) (14.8) (14.8)
75~79 3790 1895 5685 5685
(%) (15.4) (16.0) (15.6) (15.6)
80~84 3220 1934 5154 5154
(%) (13.1) (16.4) (14.2) (14.2)
85~89 1517 1291 2808 2808
(%) (6.2) (10.9) (7.7) (7.7)
90~94 318 318 636 636
(%) (1.3) (2.7) (1.7) (1.7)
95≦ 41 42 83 83
(%) (0.2) (0.4) (0.2) (0.2)
Subtotal 24,551 11,813 36,364 36,364
(%) (100.0) (100.0) (100.0) (100.0)
Table 6 Incident dialysis patient distribution by gender and age
(Continued)
Unknown 10 3 13 13
No information available
Total 24,561 11,816 36,377 36,377
Mean age 68.14 70.91 69.04 69.04
S.D. 13.20 13.60 13.39 13.39
Values in parentheses under each figure represent the percentage relative to
the subtotal in each column
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 Outcome (transfer, death, dropout, or
transplantation)
 Outcome date
 (in case of facility transfer) Facility code
 Cause of death
The following were added to the above basic survey
items and were surveyed using both paper and electronic
media.
 Current status of the combination of PD + HD
 Treatment history of PD
 Number of past renal transplantations
 Frequency of dialysis session per week
 Dialysis time per session
 Blood flow rate
 Dilution mode in HDF
 Substitution fluid volume per HDF session
 Body height
 Predialysis and postdialysis body weight
 Predialysis and postdialysis blood urea nitrogen
(BUN) concentration
 Predialysis and postdialysis serum creatinine
concentration
 Predialysis serum albumin concentration
 Predialysis serum C-reactive protein (CRP)
concentration
 Predialysis serum calcium concentration
 Predialysis serum phosphorus concentration
 Measurement method for serum parathyroid
hormone (PTH) concentration
 Intact and whole PTH concentration
 Predialysis hemoglobin (Hb) concentration
 Use or nonuse of antihypertensive agent
 Smoking habit
 History of diabetes
 History of myocardial infarction
 History of cerebral hemorrhage
 History of cerebral infarction
 History of major amputation
Table 7 Prevalent dialysis patient distribution by gender and
age
Age at the end
of 2014
Male Female Subtotal No information
available
Total
<5 21 20 41 41
(%) (0.0) (0.0) (0.0) (0.0)
5~9 15 17 32 32
(%) (0.0) (0.0) (0.0) (0.0)
10~14 23 21 44 44
(%) (0.0) (0.0) (0.0) (0.0)
15~19 72 37 109 109
(%) (0.0) (0.0) (0.0) (0.0)
20~24 152 94 246 246
(%) (0.1) (0.1) (0.1) (0.1)
25~29 455 227 682 682
(%) (0.2) (0.2) (0.2) (0.2)
30~34 1165 599 1764 1764
(%) (0.6) (0.5) (0.6) (0.6)
35~39 2771 1254 4025 4025
(%) (1.4) (1.1) (1.3) (1.3)
40~44 5985 2611 8596 8596
(%) (3.0) (2.3) (2.8) (2.8)
45~49 9334 3971 13,305 13,305
(%) (4.7) (3.5) (4.3) (4.3)
50~54 12,319 5594 17,913 17,913
(%) (6.2) (5.0) (5.8) (5.8)
55~59 17,067 8283 25,350 25,350
(%) (8.6) (7.4) (8.2) (8.2)
60~64 26,673 13,679 40,352 40,352
(%) (13.5) (12.2) (13.0) (13.0)
65~69 34,272 17,987 52,259 52,259
(%) (17.3) (16.1) (16.9) (16.9)
70~74 31,614 17,753 49,367 49,367
(%) (16.0) (15.9) (15.9) (15.9)
75~79 26,319 15,932 42,251 42,251
(%) (13.3) (14.2) (13.6) (13.6)
80~84 18,970 13,117 32,087 32,087
(%) (9.6) (11.7) (10.3) (10.3)
85~89 8681 7978 16,659 16,659
(%) (4.4) (7.1) (5.4) (5.4)
90~94 1959 2428 4387 4387
(%) (1.0) (2.2) (1.4) (1.4)
95≦ 258 360 618 618
(%) (0.1) (0.3) (0.2) (0.2)
Subtotal 198,125 111,962 310,087 310,087
Table 7 Prevalent dialysis patient distribution by gender and
age (Continued)
(%) (100.0) (100.0) (100.0) (100.0)
Unknown 16 5 21 21
No information available
Total 198,141 111,967 310,108 310,108
Mean age 66.75 68.94 67.54 67.54
S.D. 12.36 12.60 12.49 12.49
Values in parentheses under each figure represent the percentage relative to
the subtotal in each column
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 History of encapsulating peritoneal sclerosis (EPS)
The following were added to the basic survey items
and were collected only by the USB survey.
 Serum total cholesterol concentration
 Serum high-density lipoprotein cholesterol
(HDL-C) concentration
 Predialysis systolic blood pressure
 Predialysis diastolic blood pressure
 Predialysis pulse rate
The following were surveyed only for PD patients and
were collected only by the USB survey.
 PD vintage
 Number of months in which PD was performed
in 2014
 History of peritoneal equilibrium test (PET)
 Four-hour creatinine concentration dialysate/plasma
ratio in PET (PET Cr D/P ratio)
 Type of PD fluid (PD fluid type)
 Volume of PD fluid per day (PD fluid volume)
 PD treatment time per day
 Daily urine volume (Urine volume)
 Mean ultrafiltration (UF) volume per day
(UF volume)
 Kt/V by residual kidney (Residual kidney Kt/V)
 Kt/V by PD (PD Kt/V)
 Changing maneuver of PD fluids
 Use or nonuse of automated peritoneal dialysis
(APD) machine
 Past histories of peritonitis during 2014
 Past histories of exit-site infections during 2014Calculation of survival rate
The cumulative survival rate after the start of dialysis
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Table 10 Annual changes of primary disease in the incident and prevalent dialysis patients
Incident patients
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Diabetes 29.9 30.7 31.9 33.1 33.9 35.7 36.2 36.6 38.1 39.1 41.0
Chronic glomerulonephritis 41.4 40.5 39.4 38.9 36.6 35.0 33.6 32.5 32.4 31.9 29.1
Nephrosclerosis 6.2 6.1 6.3 6.4 6.8 6.7 7.0 7.6 7.6 7.8 8.5
PKD 2.6 2.5 2.4 2.5 2.4 2.4 2.2 2.4 2.3 2.4 2.3
RPGN 0.8 0.8 0.8 0.8 1.1 0.9 0.9 1.0 1.0 1.1 1.2
Lupus 1.2 1.2 1.1 1.3 1.0 1.1 1.2 0.9 1.0 0.9 0.7
Chronic pyelonephritis 1.1 1.4 1.2 1.1 1.2 1.1 1.1 1.0 1.1 0.9 1.0
Undetermined 3.3 3.9 4.5 5.0 5.5 5.6 6.1 7.6 9.0 8.4 8.8
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Diabetes 41.3 42.0 42.9 43.4 43.3 44.5 43.6 44.3 44.2 43.8 43.5
Chronic glomerulonephritis 28.1 27.4 25.6 23.8 22.8 21.9 21.0 20.2 19.4 18.8 17.8
Nephrosclerosis 8.8 9.0 9.4 10.0 10.6 10.7 11.7 11.8 12.3 13.1 14.2
PKD 2.7 2.3 2.4 2.3 2.5 2.3 2.4 2.5 2.5 2.5 2.7
RPGN 1.1 1.1 1.2 1.3 1.2 1.2 1.2 1.3 1.3 1.4 1.4
Lupus 0.8 0.8 0.8 0.8 0.8 0.7 0.8 0.7 0.7 0.7 0.7
Chronic pyelonephritis 0.9 1.0 0.8 0.8 0.7 0.7 0.8 0.7 0.8 0.8 0.7
Undetermined 9.3 9.5 9.9 10.2 10.6 10.7 10.7 10.9 11.0 11.3 11.3
Prevalent patients
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Diabetes 18.2 19.2 20.4 21.6 22.7 24.0 25.1 26.0 27.2 28.1 29.2
Chronic glomerulonephritis 58.8 57.7 56.6 55.4 54.1 52.5 51.1 49.7 49.6 48.2 46.6
Nephrosclerosis 3.4 3.6 3.8 4.0 4.2 4.4 4.5 4.8 5.0 5.1 5.3
PKD 3.3 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.3 3.3 3.3
RPGN 1.9 1.8 1.7 1.6 1.6 1.5 1.5 1.4 1.4 1.3 1.3
Lupus 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.0 1.0 1.0 0.9
Chronic pyelonephritis 0.5 0.5 0.5 0.5 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Undetermined 2.9 3.1 3.2 3.6 3.9 4.2 4.4 5.0 5.6 5.9 6.3
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Diabetes 30.2 31.4 32.3 33.4 34.2 35.1 35.9 36.7 37.1 37.6 38.1
Chronic glomerulonephritis 45.1 43.6 42.2 40.4 39.0 37.6 36.2 34.8 33.6 32.4 31.3
Nephrosclerosis 5.7 5.9 6.2 6.5 6.8 7.1 7.5 7.9 8.3 8.7 9.1
PKD 3.4 3.3 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.5 3.5
RPGN 1.3 1.2 1.2 1.2 1.1 1.1 1.1 1.0 1.0 1.0 1.0
Lupus 0.9 0.9 0.9 0.9 0.8 0.8 0.8 0.8 0.8 0.7 0.7
Chronic pyelonephritis 0.6 0.6 0.6 0.7 0.7 0.7 0.7 0.7 0.8 0.8 0.8
Undetermined 6.4 6.6 7.0 7.4 7.6 7.7 8.0 8.2 8.5 8.7 8.9
PKD polycystic kidney disease, RPGN rapidly progressive glomerulonephritis
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of JSDT
I. Outline of JSDT Renal Data Registry (JRDR)
II. Results and discussion from JRDRChapter l: Basic demographics
Chapter 2: Current status of microbiological quality
of dialysis fluid and its control
Chapter 3: Current status of hemodiafiltration
Chapter 4: Current status of peritoneal dialysis
Fig. 3 Annual changes in the distributions of three major primary diseases in the incident patients (left) and the prevalent patients (right)
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Chapter 1: Basic demographics
Number of dialysis patients
Table 1 shows a summary of the dynamics of dialysis pa-
tients in Japan at the end of 2014. The number of facil-
ities that responded to the facility survey in 2014 was
4330, an increase of 62 (1.4%) from 4268 facilities in
2013. Dialysis facilities have been continuously increas-
ing by 100 or less every year since 2000. In Table 1, data
on dialysis vintage and the longest dialysis vintage were
obtained from the patient survey. All the other results
were obtained from the facility survey.Fig. 4 Annual increasing rates of incident dialysis patients from
diabetes and chronic glomerulonephritisAs determined from the facility survey, the preva-
lent dialysis patients in Japan at the end of 2014 were
320,448 (Table 1). Table 2 shows changes in number
of prevalent, incident, and deceased dialysis patients
over the last 20 years. The number of dialysis patients
in 2014 increased by 6010, which was greater than
4431 in 2013. However, the increasing rate in preva-
lent dialysis patients has generally decreased since
2000. The annual increasing rate of the prevalent dia-
lysis patients is defined as the ratio of the increase in
dialysis patients each year to the dialysis patients at
the end of the previous year. The future trend of dia-
lysis patient population in Japan has been estimated
by assuming that this trend of annual rate increase
continues in the future. As reported previously, the
dialysis patient population in Japan is expected to
reach the maximum (approximately 348,000) around
2021 and then start decreasing [5].
The number of incident dialysis patients was 38,327 in
2014, as shown by the facility survey. The annual num-
ber of incident dialysis patients continued to increase
from the start of the survey. Since 2008, incident dialysis
patients remained around 38,000 (Table 2).
The annual increasing rates of incident dialysis pa-
tients from 2002 adjusted by the recovery rate for the
facility survey are plotted in Fig. 1, similarly to the 2013
survey [2]. According to the regression line for the
annual increasing rates of incident dialysis patients, the
turning point when the incident dialysis patients stop
increasing was expected to be in 2013, as shown in the
2013 survey report [2]. These lines of evidences sug-
gested that incident dialysis patients will gradually de-
crease in the future.
Table 11 Causes of death in incident dialysis patients
Cause of death Male Female Subtotal No information
available
Total
Heart failure 335 212 547 547
(%) (22.8) (25.5) (23.8) (23.8)
Cerebrovascular
disorder
67 37 104 104
(%) (4.6) (4.5) (4.5) (4.5)
Infectious disease 386 206 592 592
(%) (26.3) (24.8) (25.8) (25.8)
Hemorrhage 31 21 52 52
(%) (2.1) (2.5) (2.3) (2.3)
Malignant tumors 186 77 263 263
(%) (12.7) (9.3) (11.4) (11.4)
Cachexia/Uremia 60 39 99 99
(%) (4.1) (4.7) (4.3) (4.3)
Cardiac infarction 46 29 75 75
(%) (3.1) (3.5) (3.3) (3.3)
Potassium poisoning/
Sudden death
23 15 38 38
(%) (1.6) (1.8) (1.7) (1.7)
Chronic hepatitis/
Cirrhosis
15 10 25 25
(%) (1.0) (1.2) (1.1) (1.1)
Suicide/Refusal of
treatment (dialysis)
18 3 21 21
(%) (1.2) (0.4) (0.9) (0.9)
Intestinal obstruction 14 11 25 25
(%) (1.0) (1.3) (1.1) (1.1)
Pulmonary thrombus/
Pulmonary embolus
8 1 9 9
(%) (0.5) (0.1) (0.4) (0.4)
Death due to
disaster
8 3 11 11
(%) (0.5) (0.4) (0.5) (0.5)
Other causes 156 102 258 258
(%) (10.6) (12.3) (11.2) (11.2)
Unspecified 115 65 180 180
(%) (7.8) (7.8) (7.8) (7.8)
Subtotal 1468 831 2299 2299
(%) (100.0) (100.0) (100.0) (100.0)
No information available
Total 1468 831 2299 2299
Values in parentheses under each figure represent the percentage relative to
the subtotal in each column
Table 12 Causes of deaths in prevalent dialysis patients
Cause of death Male Female Subtotal No information
available
Total
Heart failure 4800 2975 7775 7775
(%) (25.2) (28.3) (26.3) (26.3)
Cerebrovascular
disorder
1329 769 2098 2098
(%) (7.0) (7.3) (7.1) (7.1)
Infectious disease 4066 2096 6162 6162
(%) (21.4) (20.0) (20.9) (20.9)
Hemorrhage 280 191 471 471
(%) (1.5) (1.8) (1.6) (1.6)
Malignant tumors 1951 718 2669 2669
(%) (10.3) (6.8) (9.0) (9.0)
Cachexia/Uremia 652 518 1170 1170
(%) (3.4) (4.9) (4.0) (4.0)
Cardiac infarction 868 390 1258 1258
(%) (4.6) (3.7) (4.3) (4.3)
Potassium poisoning/
Sudden death
551 243 794 794
(%) (2.9) (2.3) (2.7) (2.7)
Chronic hepatitis/
Cirrhosis
206 72 278 278
(%) (1.1) (0.7) (0.9) (0.9)
Suicide/Refusal of
treatment (dialysis)
166 49 215 215
(%) (0.9) (0.5) (0.7) (0.7)
Intestinal obstruction 181 129 310 310
(%) (1.0) (1.2) (1.0) (1.0)
Pulmonary thrombus/
Pulmonary embolus
55 24 79 79
(%) (0.3) (0.2) (0.3) (0.3)
Death due to
disaster
112 45 157 157
(%) (0.6) (0.4) (0.5) (0.5)
Other causes 1603 1147 2750 2750
(%) (8.4) (10.9) (9.3) (9.3)
Unspecified 2209 1130 3339 3339
(%) (11.6) (10.8) (11.3) (11.3)
Subtotal 19,029 10,496 29,525 29,525
(%) (100.0) (100.0) (100.0) (100.0)
No information
available
Total 19,029 10,496 29,525 29,525
Values in parentheses under each figure represent the percentage relative to
the subtotal in each column
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2014 was 30,707 (Table 1). The annual count of
deaths continued to increase until 2011, but it hasbeen around 30,000 since 2012 [2]. Similarly to the
previous report, the trend of the annual increasing
rates of deceased patients over the past 12 years from
Table 13 Annual changes in major causes of death
Cause of death 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Cardiac failure 29.9 28.2 25.4 24.1 23.9 24.1 24.3 23.2 25.5 25.1 25.0
Infectious disease 12.2 12.6 13.8 14.6 14.9 15.0 16.3 16.6 16.3 15.9 18.5
Malignant tumor 7.4 7.3 7.2 7.7 8.1 7.7 7.6 8.3 8.5 8.5 8.5
Cerebrovascular disease 13.5 14.1 13.5 12.9 12.6 12.1 11.3 11.3 11.6 11.2 10.7
Cardiac infarction 5.7 7.1 7.5 7.4 8.4 7.9 7.4 7.0 7.4 7.4 6.2
Others 4.1 4.5 5.8 6.3 6.7 7.0 7.7 7.9 9.1 9.0 9.7
Unspecified 2.6 2.8 3.2 2.5 3.5 3.9 3.6 8.1 5.7 6.6 5.6
Cause of death 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cardiac failure 25.1 25.8 24.9 24.0 23.7 23.6 27.0 26.6 27.2 26.8 26.3
Infectious disease 18.8 19.2 19.9 18.9 19.9 20.7 20.3 20.3 20.4 20.8 20.9
Malignant tumor 9.0 9.0 9.2 9.2 9.2 9.4 9.8 9.1 9.1 9.4 9.0
Cerebrovascular disease 10.6 9.8 9.4 8.9 8.6 8.4 8.1 7.7 7.5 7.2 7.1
Cardiac infarction 5.4 5.1 4.4 4.4 4.1 4.0 4.7 4.6 4.5 4.3 4.3
Others 10.3 9.1 9.5 9.7 9.7 10.0 6.6 8.4 8.5 8.8 9.3
Unspecified 6.5 7.3 8.3 10.3 10.9 10.6 10.9 10.8 10.5 10.8 11.3
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deaths remained around 4% until 2011 with slight
yearly fluctuations. However, the increasing rates fol-
lowing 3 years (2012–2014) was almost 0%. The re-
gression line for the increasing rates of the annual
number of deaths between 2012 and 2014 is obviously
decreasing. If this trend continues, the annual number
of deaths stops increasing in 2017. However, it can
also be interpreted that the rate of increase in the an-
nual number of deaths has fluctuated since 2012, re-
quiring careful attention to future trends.
In the 4330 facilities that responded to the facility
survey questionnaire, the total number of bedsideTable 14 Annual crude death rate
Year Crude death rate (%) Year Crude death rate (%)
1993 9.4 2004 9.4
1994 9.5 2005 9.5
1995 9.7 2006 9.2
1996 9.4 2007 9.4
1997 9.4 2008 9.8
1998 9.2 2009 9.6
1999 9.7 2010 9.8
2000 9.2 2011 10.2
2001 9.3 2012 10.0
2002 9.2 2013 9.8
2003 9.3 2014 9.7consoles was 131,555, an increase of 3405 (2.7%)
from the previous year. The capacity for simultan-
eous hemodialysis treatments in all facilities was
129,860, and the capacity for the maximum dialysis
patients was 432,433, increases of 2.9 and 2.4% from
the previous year, respectively. As mentioned above,
the total number of patients on chronic dialysis in
Japan is expected to reach a maximum of approxi-
mately 348,000 in 2021 and then gradually decrease;
this is expected even when taking into consideration
the number of patients treated in dialysis facilities
that did not respond to this survey [5]. Therefore,
the capacity for dialysis patients in 2014 had been
already larger than the expected number of the max-
imum dialysis patients.
The percentage of patients on daytime dialysis was
84.1% of the dialysis patients in 2014, which was 0.4%
higher than the previous year (Table 1). In contrast, the
nighttime dialysis patient was 12.9%, which was 0.3%
lower than 13.2% in the previous year. The absolute num-
ber of patients on nighttime dialysis remained in the range
of 41,000–42,000 over the last 10 years (Table 3). The
number of patients on home HD was 529, an increase of
68 (14.8%) from 461 in the previous year and which has
been increasing rapidly since 2006 (Table 3).
The prevalent patients on PD was 9255, which was 2.9%
of all dialysis patients. Although the number of PD patients
was maximum at 9858 in 2009, it had been gradually
decreasing since then (Table 3). The count of PD + HD pa-
tients was 1913 in the 2014 survey, and it had remained
around 1900 since 2009. The count of non-PD + catheter
Masakane et al. Renal Replacement Therapy  (2017) 3:18 Page 21 of 43patients, it was probably for peritoneal lavage, was 278 and
that of PD dropout patients during 2014 was 193.
As shown in Table 3, the number of hemodiafiltra-
tion (HDF) patients had been rapidly increasing since
2012 and reached 43,283 in 2014. The demographics
of HDF patients are described in detail in Chapter 3:
Current status of hemodiafiltration.
According to the patient survey, the longest dialysis
vintage was 46 years and 6 months (Table 1). Table 4
shows the total number of dialysis patients in each pre-
fecture of Japan determined from the facility survey.
Mean age
The dialysis patient population in Japan is aging yearly.
Table 5 shows the changes in the mean age of the preva-



























1983 9856 0.818 0.747 0.680 0.630 0.585 0.552 0.519
1984 10,687 0.816 0.735 0.670 0.619 0.576 0.536 0.495
1985 11,582 0.794 0.720 0.659 0.607 0.561 0.517 0.481
1986 12,585 0.798 0.724 0.665 0.616 0.563 0.516 0.474
1987 13,510 0.814 0.737 0.669 0.605 0.552 0.502 0.457
1988 14,719 0.824 0.739 0.664 0.599 0.541 0.493 0.450
1989 14,505 0.848 0.760 0.684 0.613 0.555 0.506 0.460
1990 16,495 0.838 0.748 0.672 0.606 0.551 0.497 0.454
1991 18,151 0.827 0.734 0.660 0.595 0.535 0.484 0.440
1992 19,837 0.820 0.727 0.650 0.585 0.527 0.479 0.434
1993 20,814 0.832 0.742 0.666 0.596 0.540 0.489 0.444
1994 21,307 0.829 0.742 0.668 0.602 0.542 0.488 0.445
1995 22,796 0.840 0.753 0.678 0.608 0.549 0.500 0.456
1996 24,830 0.831 0.749 0.672 0.607 0.553 0.505 0.454
1997 25,391 0.837 0.751 0.680 0.619 0.562 0.511 0.465
1998 26,697 0.844 0.765 0.697 0.634 0.573 0.522 0.473
1999 27,631 0.850 0.773 0.705 0.639 0.579 0.527 0.480
2000 29,125 0.855 0.777 0.711 0.647 0.588 0.533 0.487
2001 30,660 0.854 0.777 0.707 0.641 0.585 0.532 0.484
2002 31,333 0.857 0.780 0.712 0.649 0.589 0.533 0.484
2003 32,358 0.859 0.785 0.716 0.653 0.594 0.538 0.490
2004 33,458 0.865 0.790 0.723 0.660 0.600 0.544 0.492
2005 34,534 0.861 0.789 0.721 0.656 0.596 0.538 0.484
2006 35,960 0.870 0.798 0.729 0.666 0.604 0.546 0.493
2007 36,711 0.866 0.794 0.725 0.658 0.594 0.537 0.487
2008 37,787 0.866 0.796 0.727 0.660 0.597 0.542
2009 38,313 0.872 0.797 0.727 0.662 0.605
2010 38,213 0.876 0.803 0.732 0.669
2011 37,946 0.872 0.797 0.729
2012 36,278 0.891 0.828
2013 36,369 0.897patient survey. The mean age of the incident dialysis pa-
tients in 2014 was 69.0 ± 13.4 years [mean ± standard de-
viation (S.D.)] and that of the prevalent dialysis patients
was 67.5 ± 12.5 years. In last two decades from 1994 to
2014, the mean age of dialysis patients had become
6.0 years older from 57.3 to 63.3 years in the first dec-
ade, and 4.2 years older from 63.3 to 67.5 years in the
second decade. Similarly, the mean age of incident dialy-
sis patients had become 5.3 years older from 60.4 to
65.8 years in the first decade and from 65.8 to 69.0 years
in the second decade. These findings showed that the
rate of aging of both prevalent and incident dialysis pa-
tients was also slowing down. The incident patient dis-
tribution by gender and age was summarized in Table 6,
and the prevalent patient distribution by gender and age


























0.480 0.450 0.419 0.389 0.365 0.342 0.322 0.301
0.461 0.430 0.402 0.373 0.348 0.323 0.302 0.282
0.440 0.409 0.380 0.355 0.330 0.307 0.284 0.266
0.439 0.402 0.373 0.345 0.321 0.299 0.278 0.261
0.418 0.385 0.357 0.331 0.306 0.286 0.264 0.245
0.412 0.377 0.346 0.319 0.296 0.274 0.252 0.234
0.421 0.384 0.352 0.326 0.300 0.279 0.258 0.241
0.413 0.379 0.348 0.320 0.295 0.274 0.255 0.238
0.402 0.370 0.340 0.313 0.289 0.268 0.249 0.231
0.396 0.363 0.335 0.309 0.285 0.265 0.245 0.228
0.406 0.373 0.342 0.316 0.291 0.267 0.249 0.232
0.407 0.372 0.340 0.311 0.288 0.267 0.246 0.227
0.416 0.381 0.349 0.319 0.295 0.272 0.249 0.228
0.416 0.380 0.348 0.319 0.292 0.267 0.247 0.228
0.422 0.385 0.351 0.322 0.294 0.270 0.249 0.228
0.431 0.395 0.362 0.332 0.304 0.278 0.256 0.235
0.439 0.399 0.362 0.330 0.300 0.272 0.250 0.231
0.443 0.403 0.367 0.333 0.305 0.280 0.256
0.441 0.401 0.364 0.330 0.299 0.272
0.439 0.397 0.359 0.327 0.298























































1983 0.282 0.265 0.249 0.235 0.222 0.207 0.193 0.182 0.173 0.162 0.151 0.142 0.131 0.120 0.110 0.103
1984 0.264 0.247 0.233 0.221 0.207 0.194 0.183 0.174 0.162 0.153 0.144 0.135 0.125 0.117 0.108
1985 0.248 0.231 0.216 0.202 0.187 0.174 0.163 0.151 0.142 0.133 0.124 0.116 0.106 0.099
1986 0.244 0.228 0.215 0.203 0.191 0.178 0.168 0.157 0.148 0.139 0.130 0.120 0.110
1987 0.230 0.213 0.197 0.184 0.175 0.164 0.154 0.143 0.134 0.125 0.117 0.109
1988 0.218 0.203 0.190 0.180 0.168 0.157 0.147 0.138 0.129 0.121 0.111
1989 0.225 0.210 0.195 0.184 0.171 0.159 0.149 0.140 0.130 0.121
1990 0.222 0.207 0.193 0.181 0.169 0.157 0.145 0.136 0.127
1991 0.217 0.202 0.189 0.177 0.165 0.154 0.144 0.134
1992 0.212 0.198 0.184 0.171 0.158 0.146 0.136
1993 0.215 0.199 0.185 0.172 0.160 0.150
1994 0.211 0.197 0.184 0.171 0.159
1995 0.209 0.194 0.179 0.167
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Three major primary diseases of end-stage kidney dis-
ease (ESKD) were diabetes, chronic glomeruloneph-
ritis, and nephrosclerosis. The three major and other
primary diseases of ESKD were summarized by gen-
der and age in the incident patients (Table 8) and in
the prevalent patients (Table 9). Diabetes was the
most frequent primary disease as 43.5%, followed by
chronic glomerulonephritis as 17.8% (Table 10 upper
panel). The number and percentage of diabetes of the
cause of ESKD on the incident dialysis patients had
been increased until the end of 2009 and reached
16,549 and 44.5%, respectively, in 2009 (Table 10
upper panel, Fig. 3 Left). However, they had stopped
increasing and started decreasing since 2011. Annualincreasing rates of chronic glomerulonephritis and
diabetes after 2002 were plotted in Fig. 4. The in-
creasing rates were collected by the responsive rate to
the survey. The increasing rate of diabetes had been
positive until 2009 but turned to be negative since
2012. It suggests that the number of the incident dia-
lysis patients with diabetes is expected to gradually
decrease continuously in the future. In contrast, the
increasing rate of chronic glomerulonephritis had
been negative for more than the recent 10 years, indi-
cating that the number of the incident dialysis pa-
tients with chronic glomerulonephritis continued to
decrease. Nephrosclerosis was the third most com-
mon primary disease (14.2%) after diabetes and
chronic glomerulonephritis. In accordance with the
Table 16 Facility distribution on ET measurement by frequency and concentration
Endotoxin concentration
in dialysis fluid (EU/ml)
Every day Every week Every 2 weeks Every month Several times
per year
Once a year None Subtotal Unspecified No information
available
Total
<0.001 20 131 205 2295 280 233 1 3165 2 3167
(%) (0.6) (4.1) (6.5) (72.5) (8.8) (7.4) (0.0) (100.0)
0.001≦, <0.01 5 22 27 371 75 46 546 2 548
(%) (0.9) (4.0) (4.9) (67.9) (13.7) (8.4) (100.0)
0.01≦, <0.05 1 9 10 123 37 31 211 211
(%) (0.5) (4.3) (4.7) (58.3) (17.5) (14.7) (100.0)
0.05≦, <0.1 1 2 39 12 9 63 63
(%) (1.6) (3.2) (61.9) (19.0) (14.3) (100.0)
0.1≦, <0.25 1 5 26 9 7 48 48
(%) (2.1) (10.4) (54.2) (18.8) (14.6) (100.0)
0.25≦, <0.5 1 11 2 6 20 20
(%) (5.0) (55.0) (10.0) (30.0) (100.0)
0.5≦ 1 2 15 1 3 22 22
(%) (4.5) (9.1) (68.2) (4.5) (13.6) (100.0)
Subtotal 27 164 252 2880 416 335 1 4075 4 4079
(%) (0.7) (4.0) (6.2) (70.7) (10.2) (8.2) (0.0) (100.0)
Unspecified 1 1 4 5 11 79 22 63 164
(%) (1.0) (1.0) (4.0) (5.0) (10.9) (78.2) (100.0)
No information available 53 2 6 61
(%) (100.0) (100.0)
Total 27 165 253 2884 421 346 133 4229 69 6 4304
(%) (0.6) (3.9) (6.0) (68.2) (10.0) (8.2) (3.1) (100.0)
Values in parentheses under each figure represent the percentage relative to the subtotal in each row













None Subtotal Unspecified No information
available
Total
<0.1 11 100 185 1962 273 273 1 2805 6 2811
(%) (0.4) (3.6) (6.6) (69.9) (9.7) (9.7) (0.0) (100.0)
0.1≦, <1 18 40 364 68 60 550 1 551
(%) (3.3) (7.3) (66.2) (12.4) (10.9) (100.0)
1≦, <10 3 6 23 267 44 29 372 372
(%) (0.8) (1.6) (6.2) (71.8) (11.8) (7.8) (100.0)
10≦, <100 1 1 5 111 20 17 1 156 156
(%) (0.6) (0.6) (3.2) (71.2) (12.8) (10.9) (0.6) (100.0)
100≦ 1 2 1 22 9 5 40 40
(%) (2.5) (5.0) (2.5) (55.0) (22.5) (12.5) (100.0)
Subtotal 16 127 254 2726 414 384 2 3923 7 3930
(%) (0.4) (3.2) (6.5) (69.5) (10.6) (9.8) (0.1) (100.0)
Unspecified 1 6 18 8 11 141 185 79 264
(%) (0.5) (3.2) (9.7) (4.3) (5.9) (76.2) (100.0)
No information
available
99 99 4 7 110
(%) (100.0) (100.0)
Total 16 128 260 2744 422 395 242 4207 90 7 4304
(%) (0.4) (3.0) (6.2) (65.2) (10.0) (9.4) (5.8) (100.0)
Values in parentheses under each figure represent the percentage relative to the subtotal in each row
TVC total viable microbial count
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Table 18 Facility distribution on microbial measurement by cultivating medium and sampling volume
Sampling volume Nutrient agar R2A TGEA Blood agar TSA Others Subtotal Unspecified No information available Total
<1 54 161 45 3 3 12 278 22 300
(%) (19.4) (57.9) (16.2) (1.1) (1.1) (4.3) (100.0)
1≦, < 10 90 404 44 6 5 14 563 42 605
(%) (16.0) (71.8) (7.8) (1.1) (0.9) (2.5) (100.0)
10≦, <50 62 645 352 4 13 74 1150 25 1175
(%) (5.4) (56.1) (30.6) (0.3) (1.1) (6.4) (100.0)
50≦, < 100 45 642 571 1 13 85 1357 17 1 1375
(%) (3.3) (47.3) (42.1) (0.1) (1.0) (6.3) (100.0)
100≦, <500 19 263 146 2 17 447 13 460
(%) (4.3) (58.8) (32.7) (0.4) (3.8) (100.0)
500≦, < 1000 2 10 4 1 17 1 18
(%) (11.8) (58.8) (23.5) (5.9) (100.0)
1000≦, <10,000 8 5 1 14 1 15
(%) (57.1) (35.7) (7.1) (100.0)
10,000≦ 1 1 2 2
(%) (50.0) (50.0) (100.0)
Subtotal 272 2134 1168 15 36 203 3828 121 1 3950
(%) (7.1) (55.7) (30.5) (0.4) (0.9) (5.3) (100.0)
Unspecified 3 8 1 12 232 244
(%) (25.0) (66.7) (8.3) (100.0)
No information available 110 110
(%)
Total 275 2142 1169 15 36 203 3840 353 110 4304
(%) (7.2) (55.8) (30.4) (0.4) (0.9) (5.3) (100.0)
Values in parentheses under each figure represent the percentage relative to the subtotal in each row
R2A Reasoner’s No. 2 agar, TGEA Tryptone glucose extract agar, TSA Trypticase soy agar
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patients with nephrosclerosis continued to increase
steadily. The percentage of patients with “unspeci-
fied” primary diseases was the fourth highest
(11.3%). In addition, polycystic kidney disease (PKD),
rapidly progressive glomerulonephritis (RPGN),
lupus, and chronic pyelonephritis were also observed
as primary diseases. However, the percentages of
these primary diseases among the incident dialysis








Number of facilities 4136 159 4295 9 4304
(%) (96.3) (3.7) (100.0)
Values in parentheses under each figure represent the percentage relative to
the subtotal in the rowthe percentages of patients with the abovementioned
top three primary diseases and unspecified diseases,
and had shown no marked increase or decrease over
the past 20 years.
Chronic glomerulonephritis was the most common
primary disease in the prevalent dialysis patients but
the percentage of chronic glomerulonephritis has been
decreasing. In contrast, the percentage of diabetes has
been increasing and it has been the most common
primary disease in the prevalent dialysis patients since
2011. (Table 10 lower panel, Fig. 3 Right) In 2014,
the percentage of diabetes further increased (38.1%),
whereas that of chronic glomerulonephritis further
decreased (31.3%). Nephrosclerosis was the third
highest percentage of primary disease in the prevalent
dialysis patients in 2014 (9.1%). The percentage of
nephrosclerosis has been increasing. The percentage
of patients with “unspecified” primary diseases was
the fourth highest (8.9%). In addition, polycystic
Table 20 Bedside console counts by ETRF installation
Numbers of bedside
consoles
Facility status of ETRF installation Subtotal No information
available
Total
More than one bedside console
with ETRF in the facility
No bedside consoles
with ETRF in the facility
Number of bedside consoles
with ETRF
116,527 0 116,527 0 116,527
(%) (100.0) (0.0) (100.0)
Number of bedside consoles
without ETRF
11,657 3178 14,835 193 15,028
(%) (78.6) (21.4) (100.0)
Total 128,184 3178 131,362 193 131,555
(%) (97.6) (2.4) (100.0)
Values in parentheses under each figure represent the percentage relative to the subtotal in each row
ETRF endotoxin retentive filter
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RPGN were also observed as primary diseases. How-
ever, the percentages of these primary diseases were
only 0.7–3.5% and had shown no marked increase or
decrease over the past 20 years.
Causes of death
The causes of death in the incident dialysis patients
in 2014 were summarized in Table 11. The leading
cause of death of them was infectious diseases
(25.8%), followed by cardiac failure (23.8%), malignant
tumors (11.4%), other causes (11.2%), and unspecified
causes (7.8%). The causes of death in the prevalent












Without ETRF 412 120 51 10 1
(%) (13.1) (22.2) (24.8) (16.4) (3
With ETRF 2742 421 155 51 3
(%) (86.9) (77.8) (75.2) (83.6) (6
Subtotal 3154 541 206 61 4
(%) (100.0) (100.0) (100.0) (100.0) (1





Total 3167 548 211 63 4
(%)
Values in parentheses under each figure represent the percentage relative to the su
ETRF endotoxin retentive filterTable 13 shows annual changes in the percentages of
the leading causes of death in prevalent dialysis pa-
tients. Among the prevalent dialysis patients, the lead-
ing cause of death in 2014 was cardiac failure
(26.3%). The percentage of cardiac failure in prevalent
dialysis patients had markedly decreased by the early
1990s, and it has remained almost unchanged. The
second leading cause of death was infectious diseases
(20.9%); the percentage of it had been increasing by
2009, and it has remained almost unchanged. The
percentage of malignant tumors was 9.0%. The per-
centage cerebrovascular disease had continued to de-
crease since 1995 and was 7.1% in 2014. The





0.5≦ Subtotal Unspecified No information
available
Total
5 5 5 618 72 21 711
1.9) (27.8) (23.8) (15.3) (62.6) (100.0) (17.0)
2 13 16 3430 43 3473
8.1) (72.2) (76.2) (84.7) (37.4) (83.0)
7 18 21 4048 115 21 4184
00.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
2 1 31 49 4 84
36 36
8 20 22 4079 164 61 4304
btotal in each column
Table 22 Facility distribution on microbial measurement by TVC and ETRF installation on sampling
With or without ETRF when the
dialysate was sampled
<0.1 0.1~ 1~ 10~ 100 Subtotal Unspecified No information
available
Total
Without ETRF 339 108 73 45 14 579 100 32 711
(%) (12.1) (19.8) (20.2) (29.6) (35.0) (14.8) (46.1) (47.1) (17.0)
With ETRF 2461 437 289 107 26 3320 117 36 3473
(%) (87.9) (80.2) (79.8) (70.4) (65.0) (85.2) (53.9) (52.9) (83.0)
Subtotal 2800 545 362 152 40 3899 217 68 4184
(%) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
Unspecified 11 6 10 4 31 47 6 84
(%)
No information available 36 36
(%)
Total 2811 551 372 156 40 3930 264 110 4304
(%)
Values in parentheses under each figure represent the percentage relative to the subtotal in each column
ETRF endotoxin retentive filter, TVC total viable microbial count
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revised in the 2003 and 2010 surveys. We speculate that
these revisions might have had some influence on the
distributions of causes of death. These revisions were de-
tailed in the annual data report 2010 [6].Table 23 Facility distribution by endotoxin concentration and TVC
Bacterial counts in
dialysate (cfu/mL)
<0.001 0.001≦, <0.01 0.01≦, <0.05 0.05≦, <0.1 0.1≦,
<0.1 2602 153 29 9 7
(%) (92.7) (5.5) (1.0) (0.3) (0.2)
0.1~ 291 186 43 16 5
(%) (53.2) (34.0) (7.9) (2.9) (0.9)
1~ 137 125 67 11 21
(%) (37.0) (33.8) (18.1) (3.0) (5.7)
10~ 40 45 35 17 7
(%) (25.6) (28.8) (22.4) (10.9) (4.5)
100 12 6 9 4 3
(%) (30.0) (15.0) (22.5) (10.0) (7.5)
Subtotal 3082 515 183 57 43
(%) (78.6) (13.1) (4.7) (1.5) (1.1)
Unspecified 61 23 16 5 4
(%) (55.0) (20.7) (14.4) (4.5) (3.6)
No information
available
24 10 12 1 1
(%) (49.0) (20.4) (24.5) (2.0) (2.0)
Total 3167 548 211 63 48
(%) (77.6) (13.4) (5.2) (1.5) (1.2)
Values in parentheses under each figure represent the percentage relative to the su
TVC total viable microbial countAnnual crude death rate
The annual crude death rate was calculated from the
facility survey data as shown in Table 14. The annual
crude death rate is defined as the percentage of pa-
tients who died each year with respect to the mean<0.25 0.25≦, <0.5 0.5≦ Subtotal Unspecified No information
available
Total
3 3 2806 5 2811
(0.1) (0.1) (100.0)
2 4 547 4 551
(0.4) (0.7) (100.0)
5 4 370 2 372
(1.4) (1.1) (100.0)
6 6 156 156
(3.8) (3.8) (100.0)
3 3 40 40
(7.5) (7.5) (100.0)
19 20 3919 11 3930
(0.5) (0.5) (100.0)
1 1 111 151 2 264
(0.9) (0.9) (100.0)
1 49 2 59 110
(2.0) (100.0)
20 22 4079 164 61 4304
(0.5) (0.5) (100.0)
btotal in each row
Table 24 Annual changes in frequency of endotoxin measurement
Frequency of measurement (per month) 2006 2007 2008 2009 2010 2011 2012 2013 2014
1≦ 953 1153 1253 1373 2810 2914 3141 3238 3329
(%) (27.3) (31.5) (33.1) (36.0) (70.6) (71.9) (76.3) (77.7) (78.7)
<1 2535 2511 2531 2436 1170 1137 977 929 900
(%) (72.7) (68.5) (66.9) (64.0) (29.4) (28.1) (23.7) (22.3) (21.3)
Subtotal 3488 3664 3784 3809 3980 4051 4118 4167 4229
(%) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
Unspecified 185 209 244 193 92 99 77 65 69
No information available 312 179 53 48 52 27 8 3 6
Total 3985 4052 4081 4050 4124 4177 4203 4235 4304
Values in parentheses under each figure represent the percentage relative to the total in each column
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nual crude death rates between 1993 and 2014. It had
remained in the range of 9.0–9.9% until 2010 but was
in the range of 10.0–10.9% in 2011 and 2012. How-
ever, it was again in the range of 9.0–9.9% (9.8% in
2013 and 9.7% in 2014).Cumulative survival rate of incident dialysis patients
since 1983
The cumulative survival rates of the incident dialysis
patients by the year of starting dialysis since 1983
are summarized in Table 15. The 1- to 10-year sur-
vival rates were the lowest for patients who started
dialysis in 1992 and were increasing in patients in
1993 or later. However, the 5-year survival rate for
patients who started dialysis between 2003 and 2009
and the 10-year survival rate for between 1998 andTable 25 Annual change in endotoxin concentration in dialysis fluid
2006 2007 2008 200
<0.001 817 1688 – 186
(%) (29.8) (53.0) – (56.1
0.001≦, <0.05 1627 1295 – 933
(%) (59.2) (40.6) – (28.1
0.05≦ 302 203 – 527
(%) (11.0) (6.4) – (15.8
Subtotal 2746 3186 – 332
(%) (100.0) (100.0) – (100
Unspecified – 215 – 253
No information available 1239 651 – 472
Total 3985 4052 – 405
Values in parentheses under each figure represent the percentage relative to the su
In the 2008 survey, the measurement unit for the endotoxin level in the dialysate w
many errors and are not shown here2004 remained almost unchanged. The 20- or more
year survival rates tended to decrease.
Chapter 2: Current status of microbiological
quality of dialysis fluid and its control
Measurement of endotoxin concentration in dialysis
fluid
Among 4304 facilities that had at least one bedside con-
sole, 4229 facilities (98.3%) responded to the question
about the frequency for measuring endotoxin. The JSDT
standard [7] for microbiological quality of dialysis fluid
recommends that the endotoxin concentration in dialy-
sis fluid should be measured at least once a month. The
percentage of the facilities that satisfied this recommen-
dation was 78.7%, a slight increase from the previous
year as 77.7% (Table 16).
Four thousand seventy-nine facilities (94.8%) responded
to the question about the endotoxin concentration.9 2010 2011 2012 2013 2014
5 2343 2549 2787 2963 3167
) (62.1) (66.0) (70.7) (73.9) (77.6)
1115 1042 938 849 759
) (29.6) (27.0) (23.8) (21.2) (18.6)
314 271 216 195 153
) (8.3) (7.0) (5.5) (4.9) (3.8)
5 3772 3862 3941 4007 4079
.0) (100.0) (100.0) (100.0) (100.0) (100.0)
105 112 197 148 164
247 203 65 80 61
0 4124 4177 4203 4235 4304
btotal in each column
as changed from EU/L to EU/mL. The values in 2008 are considered to include
Table 26 Annual changes in frequency of TVC measurement
Frequency of measurement (per month) 2006 2007 2008 2009 2010 2011 2012 2013 2014
1≦ 371 580 751 934 2649 2794 3018 3091 3148
(%) (11.5) (16.9) (20.8) (25.8) (67.8) (70.0) (73.7) (74.7) 74.8%
<1 2857 2861 2856 2693 1260 1196 1077 1046 1059
(%) (88.5) (83.1) (79.2) (74.2) (32.2) (30.0) (26.3) (25.3) (25.2)
Subtotal 3228 3441 3607 3627 3909 3990 4095 4137 4207
(%) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
Unspecified 386 412 418 367 158 159 100 94 90
No information available 371 199 56 56 57 28 8 4 7
Total 3985 4052 4081 4050 4124 4177 4203 4235 4304
Values in parentheses under each figure represent the percentage relative to the subtotal in each column
TVC total viable microbial count
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(UPD) defined as endotoxin <0.001 EU/mL and total
viable microbial count (TVC) <0.1 cfu/mL is recom-
mended for all dialysis modalities; and standard dia-
lysis fluid defined as endotoxin <0.05 EU/mL and
TVC <100 cfu/mL is the minimum desirable quality
to ensure the safety of dialysis therapy [7]. Endotoxin
concentration of <0.001 and <0.05 EU/mL were
achieved in 77.6 and 96.2% of the 4079 facilities, re-
spectively. These percentages were higher than those
in the previous year as 73.9 and 95.1%, respectively
(Table 16).
Measurement of TVC in dialysis fluid
Four thousand twenty-seven (97.7%) among all 4304
facilities responded to the question about the fre-
quency of measurement of TVC. The JSDT standard
[7] recommends that the TVC in dialysis fluid shouldTable 27 Annual changes in TVC in dialysis fluid
TVC (cfu/mL) 2006 2007 2008 200
<0.1 508 750 915 112
(%) (48.4) (47.9) (50.7) (54
0.1≦, <100 509 775 847 901
(%) (48.5) (49.5) (46.9) (43
100≦ 32 40 43 38
(%) (3.1) (2.6) (2.4) (1.8
Subtotal 1049 1565 1805 206
(%) (100.0) (100.0) (100.0) (10
Unspecified 2036 552 575 494
No information available 900 1935 1701 149
Total 3985 4052 4081 405
Values in parentheses under each figure represent the percentage relative to the su
TVC total viable microbial countbe measured at least once a month. The percentage
of the facilities that satisfied this recommendation
was 74.8% as similar as 74.7% in 2013 (Table 17).
Three thousand nine hundred thirty facilities
(91.3%) responded to the question about the TVC in
dialysis fluid. As previously addressed, JSDT guideline
defined two qualities on TVC: UPD as <0.1 cfu/mL
and the standard dialysis fluid as 100 cfu/mL. TVC
of <0.1 and <100 cfu/mL were achieved in 71.5 and
99.0% of the facilities that responded, respectively
(Table 17).
Three thousand eight hundred forty of the facilities
(89.2%) responded to the question about the culturing
media for TVC. In the JSDT standard, Reasoner’s No. 2
agar (R2A) and tryptone glucose extract agar (TGEA)
are recommended for TVC in dialysis fluid. The survey
results showed that either of these media was used by
86.2% of the facilities that responded.9 2010 2011 2012 2013 2014
3 1819 2017 2397 2570 2811
.5) (53.1) (56.4) (63.8) (67.1) (71.5)
1542 1498 1305 1214 1079
.7) (45.0) (41.9) (34.7) (31.7) (27.5)
62 62 55 46 40
) (1.8) (1.7) (1.5) (1.2) (1.0)
2 3423 3577 3757 3830 3930
0.0) (100.0) (100.0) (100.0) (100.0) (100.0)
216 227 320 273 264
4 485 373 126 132 110
0 4124 4177 4203 4235 4304
btotal in each column
Table 28 Annual patient count by in-center extracorporeal dialysis modality
Dialysis method 2009 2010 2011 2012 2013 2014
Facility HD 253,807 262,973 270,072 268,275 264,211 255,641
HDF On-line HDF 6852 4829 4890 14,069 23,536 36,090
(%) (40.7) (32.5) (34.6) (64.8) (75.0) (83.4)
Off-line HDF 9299 9421 8573 7157 7149 6315
(%) (55.2) (63.4) (60.7) (32.9) (22.8) (14.6)
Push/Pull HDF 237 159 145 109 263 537
(%) (1.4) (1.1) (1.0) (0.5) (0.8) (1.2)
AFBF 465 458 507 390 423 341
(%) (2.8) (3.1) (3.6) (1.8) (1.3) (0.8)
HDF subtotal 16,853 14,867 14,115 21,725 31,371 43,283
(%) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
HD + HDF total 270,660 277,840 284,187 290,000 295,582 298,924
Values in parentheses under each figure represent the percentage relative to the HDF subtotal in each column
HD hemodialysis, HDF hemodiafiltration
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(91.8%) responded to the question about the sampling
volume for TVC. As previously addressed, the JSDT
standard recommended that UPD should be indicated
for all types of extracorporeal dialysis treatments [7].
The requirement of TVC for UPD is <0.1 cfu/mL so
it needs equal or greater than 10 mL of sampling vol-
ume of dialysis fluid. At least 10 mL of sampling was
performed in 77.1% of the facilities that responded
(Table 18). As previously addressed, UPD should sat-
isfy both an endotoxin <0.001 EU/mL and TVC of
<0.1 cfu/mL. However, the percentage of the facilities
that satisfied TVC of <0.1 cfu/mL (71.5%) was ap-
proximately 6% lower than that of the facilities that
satisfied the endotoxin <0.001 EU/mL (77.6%), indi-
cating the need for the improvement of dialysis fluid
quality control.
Installation of endotoxin retentive filters
Four thousand two hundred ninety-five (99.8%) responded
to questions regarding the installation of endotoxin
retentive filters (ETRFs). Among these 4295 facilities,
96.3% had at least one bedside console equipped
with an ETRF (Table 19). The 4304 facilities that
responded to the questions about the installation of
ETRFs had a total of 131,555 bedside consoles,
88.6% of which were equipped with an ETRF. The
percentage of bedside consoles equipped with an
ETRF increased by 2.6% from the previous year
(86.0%) (Table 20) [2].
Theoretically, UPD can be achieved by using an
ETRF based on its retentive performance. If facilities
cannot achieve UPD even with ETRF, these facilitiesmay have some problems in preventing the contami-
nations, such as a high contamination level of raw
water, a high level of secondary contamination, con-
tamination of ETRF itself, or contamination during
sampling. These facilities need to optimize their
maneuver of the disinfection of the entire system.
The percentages of facilities that did not achieve the
required endotoxin of <0.001 EU/mL and TVC of
<0.1 cfu/mL with ETRFs were 20.1 and 25.9%, re-
spectively (Tables 21 and 22). Standard dialysis fluid
should have an endotoxin of <0.050 EU/mL and
TVC of <100 cfu/mL. Among the facilities that had
bedside consoles equipped with an ETRF, 3.3% did
not achieve the required endotoxin and 0.8% did not
achieve the required TVC. In contrast, 66.7 and
58.5% of the facilities without ETRFs satisfied the
endotoxin and TVC of UPD, respectively. These re-
sults suggest that the technologies for purifying dia-
lysis fluid have advanced to ensure the purification
in the entire dialysate supply system. However, the
data also suggested that dialysis fluid was contami-
nated by mal-handlings of an ETRF in some cases.
Endotoxin concentration and TVC in dialysis fluid
According to the JSDT standard for on the microbio-
logical quality of dialysis fluid, UPD is recommended
for all dialysis methods [7]. UPD is defined as an
endotoxin of <0.001 EU/mL (lower than the detection
limit) and TVC of <0.1 cfu/mL [7]. Among the 4304
facilities that had at least one bedside console, 3919
(91.1%) responded to each question of endotoxin and
TVC in dialysis fluid, among which, 2602 satisfied the
above standards for UPD. They accounted for 66.4%
Table 29 Patient distribution on all types of HDF by gender
and age
Age Male Female Subtotal No information
available
Total
<5 2 2 2





15~19 7 5 12 12
(%) (0.0) (0.0) (0.0) (0.0)
20~24 24 12 36 36
(%) (0.1) (0.1) (0.1) (0.1)
25~29 87 37 124 124
(%) (0.3) (0.2) (0.3) (0.3)
30~34 199 96 295 295
(%) (0.7) (0.6) (0.7) (0.7)
35~39 514 212 726 726
(%) (1.9) (1.3) (1.7) (1.7)
40~44 1155 491 1646 1646
(%) (4.2) (3.1) (3.8) (3.8)
45~49 1671 781 2452 2452
(%) (6.1) (4.9) (5.7) (5.7)
50~54 2142 1016 3158 3158
(%) (7.8) (6.4) (7.3) (7.3)
55~59 2837 1452 4289 4289
(%) (10.4) (9.1) (9.9) (9.9)
60~64 4064 2369 6433 6433
(%) (14.9) (14.8) (14.9) (14.9)
65~69 4802 2863 7665 7665
(%) (17.6) (17.9) (17.7) (17.7)
70~74 4010 2467 6477 6477
(%) (14.7) (15.5) (15.0) (15.0)
75~79 2927 1903 4830 4830
(%) (10.7) (11.9) (11.2) (11.2)
80~84 1903 1352 3255 3255
(%) (7.0) (8.5) (7.5) (7.5)
85~89 781 706 1487 1487
(%) (2.9) (4.4) (3.4) (3.4)
90~94 171 180 351 351
(%) (0.6) (1.1) (0.8) (0.8)
95≦ 17 25 42 42
(%) (0.1) (0.2) (0.1) (0.1)
Subtotal 27,313 15,967 43,280 43,280
Table 29 Patient distribution on all types of HDF by gender
and age (Continued)
(%) (100.0) (100.0) (100.0) (100.0)
Unknown 3 3 3
No information
available
Total 27,316 15,967 43,283 43,283
Mean age 64.32 66.30 65.05 65.05
S.D. 12.40 12.27 12.39 12.39
Values in parentheses under each figure represent the percentage relative to
the subtotal in each column
HDF hemodiafiltration
Table 30 Patient distribution by in-center HD/HDF and primary
disease
Primary disease In-cnter HD (%) HDF (%)
Chronic glomerular nephritis 76,117 (29.8) 16,311 (37.7)
Chronic pyelonephritis 2456 (1.0) 462 (1.1)
RPGN 2106 (0.8) 304 (0.7)
PIH 1156 (0.5) 378 (0.9)
Unclassified nephritis 1058 (0.4) 207 (0.5)
PKD 9081 (3.6) 1593 (3.7)
Nephrosclerosis 24,036 (9.4) 3132 (7.2)
Hypertensive emergencies 2110 (0.8) 346 (0.8)
Diabetes 100,830 (39.4) 14,284 (33.0)
Lupus 1757 (0.7) 394 (0.9)
Amyloidosis 376 (0.1) 64 (0.1)
Gout 907 (0.4) 163 (0.4)
Inborn errors of metabolism 201 (0.1) 50 (0.1)
Tuberculosis 175 (0.1) 24 (0.1)
Urolithiasis 488 (0.2) 72 (0.2)
Neoplasm of kidney and
urinary tract
771 (0.3) 100 (0.2)
Urinary tract obstructive 616 (0.2) 80 (0.2)
Myeloma 245 (0.1) 23 (0.1)
Hypoplastic kidney 455 (0.2) 111 (0.3)
Undetermined 22,799 (8.9) 3763 (8.7)
Rejected kidney 1613 (0.6) 450 (1.0)
Others 6288 (2.5) 972 (2.2)
Subtotal 255,641 (100.0) 43,283 (100.0)
No information available
Total 255,641 43,283
Values in parentheses on the right side of each figure represent the
percentage relative to the subtotal in each column
HD hemodialysis, HDF hemodiafiltration, RPGN Rapidly progressive
glomerulonephritis, PIH Pregnancy-induced hypertension, PKD polycystic
kidney disease
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Table 33 Patient distribution by dilution mode and HDF modality




Subtotal Unspecified No information
available
Total
On-line HDF 29,881 1342 0 1317 32,540 1 3549 36,090
(%) (91.8) (4.1) (0.0) (4.0) (100.0)
Off-line HDF 638 4275 5 5 4923 1392 6315
(%) (13.0) (86.8) (0.1) (0.1) (100.0)
Push/Pull HDF 8 88 0 266 362 175 537
(%) (2.2) (24.3) (0.0) (73.5) (100.0)
AFBF 2 154 1 157 184 341
(%) (1.3) (98.1) (0.0) (0.6) (100.0)
Total 30,529 5859 5 1589 37,982 1 5300 43,283
(%) (80.4) (15.4) (0.0) (4.2) (100.0)
Values in parentheses under each figure represent the percentage relative to the subtotal in each row
HDF hemodiafiltration, AFBF acetate free biofiltration
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60.5% of all the facilities, which were higher than
those in the previous year, 60.8 and 54.9%, respect-
ively (Table 23).Changes in status of quality control of dialysis fluid
In the early 2000s, microbial contamination of dialysis
fluid was considered an important factor affecting the
quality of dialysis treatment. Moreover, a concern on
the high possibility of bacterial contaminations in
centralized dialysis fluid delivery system (CDDS)
widely used in Japan was raised by overseas re-
searchers. In response to this, the survey of the endo-
toxin level and TVC in dialysis fluid was started in
2006. The results have been referenced in revising the
JSDT standard and the targets of endotoxin and TVC
were changed in 2008, 2010, and 2012 [7–9]. Such a
large-scale survey on dialysis fluid quality has been
carried out and used for the revision of the standard
only in Japan. With the above historical background,
how the status of bacteriological contamination of
dialysis fluid changed between 2006 and 2014 is





Number of patients 29,881 1342 0
Mean volumes of substitution





Number of patients 638 4275 5
Mean volumes of substitution
fluid per session (L)
10.2 8.0 9.0
S.D. 6.6 2.3 1.4
HDF hemodiafiltrationThe percentage of facilities that measured endo-
toxin in dialysis fluid at least once a month was
36.0% in 2009, increased to 70.6% in 2010 because
of the revision of the medical reimbursement, and
continued to gradually increase to 78.7% in 2014
(Table 24). The measured endotoxin in dialysis fluid
decreased yearly; 77.6% of the facilities achieved the
required endotoxin of UPD (<0.001 EU/mL), and
96.2% of the facilities achieved the required endo-
toxin concentration of standard dialysis fluid
(<0.050 EU/mL) (Table 25). In the 2008 survey, the
endotoxin unit was changed from EU/L to EU/mL
in accordance with the international standards. Be-
cause many errors resulting from the misunder-
standing of the unit were found in the responses,
the endotoxin concentration in dialysis fluid in the
2008 was excluded.
The target of TVC in dialysis fluid was not included in
the JSDT guidelines on dialysate quality control stan-
dards in 2005 [16]. Owing to the revision of the standard
in 2008, it was recommended to measure TVC at least
once a month similarly as well as endotoxin level [7]. In
2007 or previously, only 10–19% of the facilities mea-





Subtotal Unspecified No information
available
Total
1317 32,540 1 3549 36,090
1.5 37.4 37.4
1.2 17.4 17.4
5 4923 0 1392 6315
1.3 8.3 8.3
0.5 3.3 3.3
Table 35 Annual changes in substitution volume of predilution online HDF
Year 1~ 10~ 20~ 30~ 40~ 50~ 60~ 70~ 80~ Subtotal Unknown Total Mean S.D.
2012 415 711 1829 2320 3373 913 1102 345 145 11,153 122 11,275 39.1 16.7
(%) (3.7) (6.4) (16.4) (20.8) (30.2) (8.2) (9.9) (3.1) (1.3) (100.0)
2013 464 936 2728 3730 6791 1558 2009 445 316 18,977 267 19,244 40.6 15.8
(%) (2.4) (4.9) (14.4) (19.7) (35.8) (8.2) (10.6) (2.3) (1.7) (100.0)
2014 1030 1347 4583 5399 10,512 2138 2693 563 450 28,715 1166 29,881 39.6 15.8
(%) (3.6) (4.7) (16.0) (18.8) (36.6) (7.4) (9.4) (2.0) (1.6) (100.0)
Values in parentheses under each figure represent the percentage relative to the subtotal in each row
HDF hemodiafiltration
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because of the revision of the medical reimbursement in
that year and it gradually increased to 74.8% in 2014
(Table 26). The percentage of facilities that satisfied
TVC for UPD (<0.1 cfu/mL) gradually increased to
71.5% in 2014. The percentage of facilities that satisfied
standard dialysis fluid (<100 cfu/mL) was 99.0%
(Table 27).
Chapter 3: Current status of hemodiafiltration
Basal characteristics of HDF patients
Since the revision of the medical reimbursement for
HDF made in April 2012 [9], the number of patients
treated by online HDF have been rapidly increasing. The
HDF patient count was 14,069 in 2012 and increased by
2.5-fold up to 36,090 in 2014 (Table 28) [2, 6, 13–15]
whereas, the count of the patients on offline HDF de-
creased from 7157 in 2012 to 6315 in 2014. The percent-
age of patients on HDF of all dialysis patients has
increased from 7.5% in 2012 to 14.5% in 2014.
The HDF patients’ distributions by age and gender
were summarized (Table 29). For both males and fe-
males, the number of patients on HDF in the age group
of 65–70 years was the largest, showing no significant
difference in the age distribution by gender.
The primary diseases of the HDF patients were com-
pared with in-center HD patients (Table 30). The preva-
lence of diabetes was lower in HDF patients than in in-
center HD patients. Chronic glomerulonephritis was theTable 36 Annual changes in substitution volume of postdilution on
Year 1~ 5~ 10~ 15~ 20~
2012 31 289 460 113 24
(%) (3.4) (31.5) (50.2) (12.3) (2.6)
2013 172 536 474 104 35
(%) (13.0) (40.6) (35.9) (7.9) (2.6)
2014 89 482 501 104 137
(%) (6.8) (36.7) (38.2) (7.9) (10.4)
Values in parentheses under each figure represent the percentage relative to the su
HDF hemodiafiltrationmost common in the HDF patients (37.7%), followed by
diabetes (33.0%). This finding may be attributable to the
fact that many of the HDF patients have a longer dialysis
vintage than the in-center HD patients.
The dialysis vintages of HDF patients were evaluated
by gender (Table 31) and were compared among various
extracorporeal dialysis modalities (Table 32). For dialysis
vintages of <20 years, the percentage of male patients
was higher than that of female patients. For dialysis vin-
tages of ≥20 years, the ratio of males to females was
nearly 1:1. Even among the patients with dialysis vin-
tages of <2 years, 7.5% underwent online HDF. The per-
centage of patients on online HDF increased with
increasing dialysis vintage. This suggests that at the time
immediately after the start of dialysis, online HDF might
be selected for the prevention of dialysis-related compli-
cations in the future.Dilution mode and substitution volume
The majority of the patients on online HDF (91.8%) was
treated by predilution, whereas that of offline HDF
(86.8%) was performed in postdilution (Table 33). The
mean substitution volume was compared between the
patients on online and offline HDF by dilution mode
(Table 34). In online HDF, the mean volumes were 39.6
and 10.6 L for predilution and postdilution, respectively.
In offline HDF, the mean volumes were 10.2 and 8.0 L
for predilution and postdilution, respectively.line HDF
Subtotal Unknown Total Mean S.D.
917 36 953 10.6 3.9
(100.0)
1321 118 1439 9.2 4.5
(100.0)
1313 29 1342 10.6 5.0
(100.0)
btotal in each row
Table 37 Annual changes in substitution volume of predilution offline HDF
Year 1~ 5~ 10~ 15~ 20~ Subtotal Unknown Total Mean S.D.
2012 20 200 207 7 22 456 29 485 9.2 3.8
(%) (4.4) (43.9) (45.4) (1.5) (4.8) (100.0)
2013 40 252 227 5 36 560 20 580 9.4 4.7
(%) (7.1) (45.0) (40.5) (0.9) (6.4) (100.0)
2014 89 222 209 15 83 618 20 638 10.2 6.6
(%) (14.4) (35.9) (33.8) (2.4) (13.4) (100.0)
Values in parentheses under each figure represent the percentage relative to the subtotal in each row
HDF hemodiafiltration
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line HDF between 2012 and 2014 are shown for the pre-
dilution (Table 35) and postdilution (Table 36) [2, 15].
For the predilution, the numbers of patients in all
groups stratified by the volume of substitution fluid in-
creased. However, the mean substitution volume in the
entire online HDF patients remained almost unchanged
at approximately 40 L in 2012–2014. The group of pa-
tients with 40–50 L of substitution volume was the lar-
gest in each year, and the percentage of this group
increased over time. For the postdilution, the numbers
of patients in the stratified groups with ≥10 L of substi-
tution fluid tended to increase. In particular, the number
of patients in the group with ≥20 L of substitution
greatly increased over time, although the absolute num-
ber was still small. This finding indicates that an increas-
ing number of patients has undergone postdilution
online HDF using a large volume of substitution fluid,
which is mainly performed in Europe.
The changes in the substitution volume per session of
offline HDF between 2012 and 2014 are shown for the
predilution (Table 37) and the postdilution (Table 38) [2,
15]. The number of patients on predilution offline HDF
was small but slightly increased, and the substitution
volume among them also tended to increase. In contrast,
in 2014, the number of patients on postdilution offline
HDF decreased by approximately 1000 from the previ-
ous year. However, the percentages of patients with dif-
ferent volumes of substitution fluid have hardly changedTable 38 Annual changes in substitution volume of postdilution off
Year 1~ 5~ 10~ 15~ 20~
2012 492 2845 1620 16 5
(%) (9.9) (31.5) (50.2) (12.3) (2.6)
2013 508 2775 1722 16 13
(%) (10.1) (55.1) (34.2) (0.3) (0.3)
2014 338 2235 1492 11 7
(%) (8.3) (54.7) (36.5) (0.3) (0.2)
Values in parentheses under each figure represent the percentage relative to the su
HDF hemodiafiltrationin the 3 years and the mean volume of substitution fluid
remained at approximately 8 L.
The dialysis prescription is usually affected by the pa-
tient’s body size. The substitution volumes for HDF ther-
apy were evaluated by body weight according to the
dilution mode and gender. In the male patients on pre-
dilution HDF with body weight <50 kg, the percentages
of the substitution volume as 20–40 and 40–80 L were
similar. In case of body weight ≥50 kg, the percentage of
those using 40–80 L of substitution fluid increased and
exceeded 60% in the group of male patients who
weighed ≥60 kg (Table 39). In the female patients on
predilution HDF with body weight <40 kg, the percent-
age of 20–40 L of substitution fluid was almost the same
as that of patients using 40–80 L. In case of body weight
≥50 kg, the percentage of 20–40 L of substitution fluid
was almost the same as 40–80 L. The titration of substi-
tution volume according to body weight was observed
only in males but not in females (Table 40). In the post-
dilution mode, the male patients with body weight
<50 kg were mostly treated with 5–10 L of substitution
volume. In the male patients with body weight 60–
70 kg, the patients treated with 10–20 L of substitution
fluid was similar to that of 5–10 L. In the patients with
body weight ≥70 kg, the percentage of patients using
10–20 L of substitution fluid was the highest (Table 41).
In the female patients, the percentage of patients using
5–10 L of substitution fluid was greater than 50% in all
weight groups (Table 42).line HDF
Subtotal Unknown Total Mean S.D.
4978 71 5049 7.8 2.3
(100.0)
5034 180 5214 7.9 2.4
(100.0)
4083 192 4275 8.0 2.3
(100.0)
btotal in each row
Table 41 Male patient distribution on postdilution HDF by




Postdialysis body weight (kg) Total
<40 40~50 50~60 60~70 70~80 80~
<5 4 39 78 38 21 10 190
(%) (10.0) (7.6) (6.7) (4.5) (6.3) (4.6) (6.1)
5~ 23 276 575 395 138 76 1483
(%) (57.5) (53.9) (49.6) (46.7) (41.3) (35.0) (47.7)
10~ 11 186 478 380 158 118 1331
(%) (27.5) (36.3) (41.2) (45.0) (47.3) (54.4) (42.8)
20~ 2 11 29 32 17 13 104
(%) (5.0) (2.1) (2.5) (3.8) (5.1) (6.0) (3.3)
40~ 0 0 0 0 0 0 0
(%) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0)
80~ 0 0 0 0 0 0 0
(%) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0)
Total 40 512 1160 845 334 217 3108
(%) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
Values in parentheses under each figure represent the percentage relative to
the subtotal in each column
HDF hemodiafiltration
Table 39 Male patient distribution on predilution HDF by




Postdialysis body weight (kg) Total
<40 40~50 50~60 60~70 70~80 80~
<5 6 67 110 87 33 9 312
(%) (3.0) (2.7) (1.7) (1.6) (1.4) (0.7) (1.7)
5~ 11 88 165 108 53 15 440
(%) (5.5) (3.5) (2.6) (2.0) (2.3) (1.1) (2.4)
10~ 22 179 335 228 91 47 902
(%) (11.1) (7.1) (5.2) (4.3) (3.9) (3.4) (5.0)
20~ 80 1022 2183 1588 610 343 5826
(%) (40.2) (40.6) (34.1) (30.1) (26.2) (24.8) (32.2)
40~ 76 1128 3511 3187 1494 927 10,323
(%) (38.2) (44.9) (54.8) (60.3) (64.2) (67.0) (57.0)
80~ 4 31 99 86 45 43 308
(%) (2.0) (1.2) (1.5) (1.6) (1.9) (3.1) (1.7)
Total 199 2515 6403 5284 2326 1384 18,111
(%) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
Values in parentheses under each figure represent the percentage relative to
the subtotal in each column
HDF hemodiafiltration
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The distributions of blood flow rate in each HDF modal-
ity were summarized in Table 43. At least half of the on-
line HDF patients were treated at a blood flow rate of
≥220 mL/min, whereas at least half of the offline HDF
patients were treated at a blood flow rate of <220 mL/Table 40 Female patient distribution on predilution HDF by




Postdialysis body weight (kg) Total
<40 40~50 50~60 60~70 70~80 80~
<5 48 79 43 17 3 0 190
(%) (3.0) (1.8) (1.6) (1.8) (1.1) (0.0) (1.9)
5~ 81 163 78 33 6 3 364
(%) (5.1) (3.6) (2.9) (3.6) (2.1) (2.2) (3.6)
10~ 136 302 131 42 9 4 624
(%) (8.5) (6.7) (4.9) (4.5) (3.2) (2.9) (6.2)
20~ 672 1664 890 297 106 44 3673
(%) (42.2) (36.9) (33.4) (32.0) (37.5) (31.9) (36.3)
40~ 641 2247 1487 520 157 80 5132
(%) (40.2) (49.9) (55.8) (56.0) (55.5) (58.0) (50.7)
80~ 15 49 38 19 2 7 130
(%) (0.9) (1.1) (1.4) (2.0) (0.7) (5.1) (1.3)
Total 1593 4504 2667 928 283 138 10,113
(%) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
Values in parentheses under each figure represent the percentage relative to
the subtotal in each column
HDF hemodiafiltrationmin. The mean blood flow rate was a little higher in pre-
dilution in online HDF but it was higher in postdilution
in offline HDF.
Table 44 shows the distributions of dialysis session
time in each HDF modality. The dialysis time per sessionTable 42 Female patient distribution on postdilution HDF by





Postdialysis body weight (kg) Total
<40 40~50 50~60 60~70 70~80 80~
<5 60 88 51 9 5 0 213
(%) (13.9) (9.5) (10.1) (6.0) (12.2) (0.0) (10.2)
5~ 255 490 259 83 24 10 1121
(%) (58.9) (52.6) (51.3) (55.3) (58.5) (50.0) (53.9)
10~ 113 336 189 53 11 8 710
(%) (26.1) (36.1) (37.4) (35.3) (26.8) (40.0) (34.1)
20~ 5 17 6 5 1 2 36
(%) (1.2) (1.8) (1.2) (3.3) (2.4) (10.0) (1.7)
40~ 0 0 0 0 0 0 0
(%)
80~ 0 0 0 0 0 0 0
(%)
Total 433 931 505 150 41 20 2080
(%) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
Values in parentheses under each figure represent the percentage relative to
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Table 45 Comparison of characteristics between in-center HD and HDF patients by dilution mode
In-center
HD
On-line HDF Off-line HDF
Predilution Postdillution Predilution Postdillution
Basic indices Number of patients 228,971 28,783 1326 634 4194
Male 147,033 18,463 824 394 2473
Male (%) 64.2 64.1 62.1 62.1 59.0
Percentage of diabetes 39.5 33.5 30.8 30.1 30.0
Age 68.1 ± 12.3 64.6 ± 12.5 64.8 ± 12.2 66.8 ± 12.1 65.7 ± 11.9
Dialysis vintage (years) 7.0 ± 7.0 9.5 ± 8.5 11.0 ± 9.3 12.0 ± 9.8 12.9 ± 10.0
Postdialysis body weight (male) 59.6 ± 12.2 61.7 ± 12.4 61.0 ± 12.3 58.2 ± 11.5 60.2 ± 12.5
Postdialysis body weight (female) 48.6 ± 10.6 49.2 ± 10.3 48.8 ± 10.1 47.3 ± 9.6 47.4 ± 9.5
Indices for urea
kinetics
dilalysis time (minute) 238.4 ± 31.4 246.8 ± 30.2 242.4 ± 29.7 240.3 ± 34.2 247.4 ± 30.4
Blood flow rate (mL/min) 204.9 ± 36.4 228.2 ± 41.0 219.9 ± 39.1 204.5 ± 36.0 212.2 ± 35.0
Kt/V (male)* 1.40 ± 0.26 1.45 ± 0.27 1.45 ± 0.26 1.39 ± 0.25 1.45 ± 0.26
Kt/V (female)* 1.62 ± 0.31 1.71 ± 0.31 1.70 ± 0.31 1.60 ± 0.32 1.69 ± 0.31
normalized protein catablic rate (g/kg/day, male)* 0.85 ± 0.17 0.87 ± 0.16 0.87 ± 0.16 0.86 ± 0.16 0.87 ± 0.17
normalized protein catablic rate (g/kg/day,
female)*
0.88 ± 0.18 0.91 ± 0.18 0.91 ± 0.17 0.89 ± 0.17 0.90 ± 0.18
Indices for nutrition Serum albumin (g/dL) 3.60 ± 0.44 3.65 ± 0.37 3.60 ± 0.41 3.52 ± 0.45 3.57 ± 0.43
Serum CRP level (mg/dL) 0.64 ± 1.94 0.49 ± 1.47 0.56 ± 1.79 0.83 ± 2.46 0.74 ± 2.09
Predialysis serum creatinin (male)* 10.98 ± 2.80 11.51 ± 2.66 11.53 ± 2.74 11.13 ± 2.81 11.10 ± 2.75
Predialysis serum creatinin (female)* 9.12 ± 2.34 9.66 ± 2.12 9.66 ± 2.11 9.16 ± 2.24 9.16 ± 2.13










Indices for CKD-MBD Predialysis serum calcium (mg/dl) 9.18 ± 0.74 9.17 ± 0.73 9.25 ± 0.75 9.34 ± 0.80 9.29 ± 0.82
Predialysis serum phosphorus (mg/dl) 5.20 ± 1.43 5.38 ± 1.42 5.31 ± 1.37 5.29 ± 1.51 5.28 ± 1.51
Intact PTH level (pg/ml) 170.0 ±
161.0








152.4 ± 36.0 154.9 ± 35.7
Indices for anemia Predialysis hemoglobin (g/dL) 10.69 ± 1.28 10.88 ± 1.24 10.80 ± 1.24 10.78 ± 1.51 10.68 ± 1.36
Note: Total number of each index was different from each other because response rate for the question was different in each other
HD hemodilaysis, HDF hemodiafiltration, CKD-MBD chronic kidney disease-mineral & bone disorder
*For the indices from age to predialysis Hb concentration, “mean ± S.D.” are shown
Table 44 Patient distribution on online/offline HDF, by dialysis time & dilution mode
HDF method <3.0 3.0~ 3.5~ 4.0~ 4.5~ 5.0~ 5.5~ 6.0~ Subtotal Unknown Total Mean S.D.
On-line HDF Predilution 55 1512 1764 18,954 2900 2980 181 267 28,613 170 28,783 4.11 0.50
(%) (0.2) (5.3) (6.2) (66.2) (10.1) (10.4) (0.6) (0.9) (100.0)
Postdilution 1 108 100 858 126 112 7 7 1319 7 1326 4.04 0.50
(%) (0.1) (8.2) (7.6) (65.0) (9.6) (8.5) (0.5) (0.5) (100.0)
Off-line HDF Predilution 4 74 20 433 42 53 0 6 632 2 634 4.00 0.57
(%) (0.6) (11.7) (3.2) (68.5) (6.6) (8.4) (0.0) (0.9) (100.0)
Postdilution 5 214 198 2822 396 483 22 35 4175 19 4194 4.12 0.51
(%) (0.1) (5.1) (4.7) (67.6) (9.5) (11.6) (0.5) (0.8) (100.0)
Values in parentheses under each figure represent the percentage relative to the subtotal in each row
HDF hemodiafiltration
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Many HDF patients tended to undergo HDF for 4.0–
4.5 h per session.Comparison between in-center HD and HDF patients
Characteristics of the patients treated by in-center HD
and HDF were compared by dilution mode (Table 45).
The patients with dialysis vintage of ≥2 years and treated
on 3 times per week dialysis program were included to
the comparison. The mean age of the in-center HD pa-
tients was the highest, whereas the online HDF patients
were younger than the patients who underwent other
types of dialysis. The dialysis vintage was the shortest in
the in-center HD patients and the longest in the offline
HDF patients. The postdialysis body weight and percent-
ile creatinine generation rate (%CGR), which is an index
of muscle mass, were high in the online HDF patients.
CRP was low in the online HDF patients. The indices re-
lated to mineral and bone disorder on chronic kidney
disease (CKD-MBD) and Hb showed no remarkable
differences between the modalities.Chapter 4: Current status of peritoneal dialysis
The results of the facility survey shown in Table 1 re-
vealed that the prevalent PD patient count was 9255 at
the end of 2014. Moreover, the number of patients who
had a PD catheter but were supposed to use it only for
peritoneal lavage was 278. The number of patients who
started PD in 2014 but stopped PD and introduced to
another method during 2014 was 193. The detailed
results of the PD survey are reported separately.
Therefore, only a basic summary of the results is in-
cluded in this report.Table 47 PD patient distribution by PD vintage and PD combinatio
Combined use of PD and
another method
<1 yr. 1 yr. ~ 2 yrs. ~ 4 yrs. ~ 6 yrs. ~
PD only 1252 948 1269 640 269
(%) (96.7) (89.8) (83.6) (73.1) (59.1)
PD + HD 1/week 35 93 219 205 151
(%) (2.7) (8.8) (14.4) (23.4) (33.2)
PD + HD 2/week 4 7 12 20 27
(%) (0.3) (0.7) (0.8) (2.3) (5.9)
PD + HD 3/week 3 3 2 2
(%) (0.3) (0.2) (0.2) (0.4)
PD + HD other frequencies 4 4 14 8 6
(%) (0.3) (0.4) (0.9) (0.9) (1.3)
Total 1295 1055 1517 875 455
(%) (100.0) (100.0) (100.0) (100.0) (100.0)
Values in parentheses under each figure represent the percentage relative to the to
Tabulation target: PD patients (including those who underwent PD and HD or HDF)
HD hemodialysis, PD peritoneal dialysisCombination therapy of PD and other dialysis modalities
Prevalent patient distributions on the combination of
PD and other dialysis modalities (PD + HD) were sum-
marized in Table 46. The main dialysis methods are cat-
egorized on the basis of the classification codes for
dialysis methods that have been conventionally used in
the patient survey. Among the 310,086 patients who
responded to questions regarding the status of PD + HD
in the patient survey, 301,063 (97.1%) underwent a non-
PD dialysis modalities such as HD (non-PD patients)
and 9023 (2.9%) underwent PD alone or PD + HD. The
count of non-PD patients increased from 2013 as
297,773, whereas that of PD patients decreased by 98
from 2013 as 9121.
Among the 301,063 of non-PD patients, 269 patients
had a PD catheter (i.e., non-PD + catheter patients).
Most of these patients were switched to HD from PD
but did not have their PD catheter removed. There was
also one non-PD + catheter patient among the 519 pa-
tients who underwent home HD. In this survey report,
non-PD + catheter patients were tentatively classified
and counted as patients who did not undergo PD in the
analysis of the survey data. Note that this is only a tenta-
tive classification and that the Committee of Renal Data
Registry (CRDR) of JSDT does not intend to standardize
the above definition.
The count of PD-only patients was 7188, which was
smaller than that in 2013 as 7324. The percentage of
PD-only patients in all 9023 PD patients was 79.7%,
which was smaller than that in 2013 as 80.3%. Moreover,
the number of patients of PD + HD was 1835, which
was larger than that in 2013 as 1797. The percentage of
PD + HD patients in the entire PD patient population
was 20.3%, which was larger than that in 2013 as 19.7%.n
8 yrs. ~ 10 yrs. ~ Subtotal No information
available
Total Mean S.D.
101 109 4588 2600 7188 2.80 2.72
(46.5) (41.3) (80.8) (77.8) (79.7)
86 113 902 642 1544 5.69 3.92
(39.6) (42.8) (15.9) (19.2) (17.1)
26 26 122 55 177 7.53 4.15
(12.0) (9.8) (2.1) (1.6) (2.0)
5 15 25 40 6.58 5.05
(1.9) (0.3) (0.7) (0.4)
4 11 51 22 73 6.47 4.99
(1.8) (4.2) (0.9) (0.7) (0.8)
217 264 5678 3344 9022 3.40 3.27
(100.0) (100.0) (100.0) (100.0) (100.0)
tal in each column
Masakane et al. Renal Replacement Therapy  (2017) 3:18 Page 42 of 43Among 1835 PD + HD patients, 1544 (84.1%) under-
went a non-PD dialysis modality once a week, 177
(9.6%) in twice a week, 40 (2.2%) in three times a week,
and one patient in four times a week. There were also
73 patients (4.0%) of PD + HD at frequencies other than
those mentioned above.
There were various main dialysis method codes in
1835 PD + HD patients (shaded area in Table 46) be-
cause the choice of a code for the main dialysis method
was just dependent on the responder’s decision.
This classification of the main dialysis modality for the
PD + HD patients have been a tentative one by CRDR, a
standardized classification for the PD + HD patients had
not been established.
PD + HD and PD vintage
Table 47 shows the prevalent patient distribution by PD +
HD and PD vintage. The responses for both the PD vin-
tage and the status of PD + HD were recovered in 5678
PD + HD patients. The percentage of PD + HD patients
even with a PD vintage of <1 year was 3.3% and increased
with PD vintage: ≥1–<2 years, 10.1%; ≥2–<4 years, 16.3%;
≥4–<6 years, 26.9%; ≥6–<8 years, 40.9%; ≥8–<10 years,
53.5%; and ≥10 years, 58.7%. The majority (82.8%) of the
PD + HD patients underwent HD or HDF once a week.
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